Adeno-associated virus vector delivery of alpha-sarcoglycan and treatment of muscular dystrophy
Patent Information
- Application Number
- JP2024124753
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-11
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-08-21
AI Technical Summary
【0053】 別の態様では、本開示は、配列番号1、4、または8に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるヌクレオチド配列を含むAAVベクタープラスミドを含む宿主細胞を提供する。例えば、宿主細胞は、配列番号1、4、または8のヌクレオチド配列を含むAAVベクタープラスミドを含む。 本発明の実施形態において、例えば以下の項目が提供される。 (項目1) 組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGAを投与するステップを含む、筋ジストロフィーの治療を必要とする対象においてそれを行う方法であって、前記rAAVが、全身投与経路を使用して、定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.0×1012vg/kg~約5.0×1015vg/kgの用量で投与される、方法。 (項目2) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.0×1012vg/kg~約2.0×1015vg/kg、約5×1012vg/kg~約1.0×1015vg/kg、約1.0×1013vg/kg~約5.0×1014vg/kg、約2.0×1013vg/kg~約3.0×1014vg/kg、または約5×1013vg/kg~約2×1014vg/kgの用量で投与される、項目1に記載の方法。 (項目3) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量で投与される、項目1に記載の方法。 (項目4) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg、約1×1014vg/kg、または約2×1014vg/kgの用量で投与される、項目1に記載の方法。 (項目5) 組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGAを投与するステップを含む、筋ジストロフィーの治療を必要とする対象においてそれを行う方法であって、前記rAAVが、全身投与経路を使用して投与され、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.85×1013vg/kg~約7.41×1013vg/kgの用量で投与される、方法。 (項目6) 前記対象の細胞におけるアルファ-サルコグリカン遺伝子発現のレベルが、前記rAAVの投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記rAAVの投与後に増加し、前記対象における血清CKレベルが、前記rAAVの投与前の血清CKレベルと比較して、前記rAAVの投与後に減少し、自発運動および比力の生成が、増加し、線維症が、軽減し、前脛骨筋の収縮誘発性損傷に対する抵抗性が、増加し、かつ/または、前記対象の筋肉組織におけるアルファ-サルコグリカン陽性線維の数が、前記rAAVの投与前の前記アルファ-サルコグリカン陽性線維の数と比較して、前記rAAVの投与後に増加する、項目1~5のいずれか一項に記載の方法。 (項目7) 前記全身投与経路が、静脈内経路である、項目1~6のいずれか一項に記載の方法。 (項目8) 前記rAAVが、注射、注入または移植によって投与される、項目1~7のいずれか一項に記載の方法。 (項目9) 前記rAAVが、注入によって投与される、項目1~8のいずれか一項に記載の方法。 (項目10) 前記rAAVが、末梢四肢静脈を介する静脈内経路によって投与される、項目1~9のいずれか一項に記載の方法。 (項目11) 前記rAAVが、配列番号1に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有するヌクレオチド配列を含む、項目1~10のいずれか一項に記載の方法。 (項目12) 前記rAAVが、配列番号1のヌクレオチド配列を含む、項目11に記載の方法。 (項目13) 前記rAAVが、配列番号2に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるポリペプチド配列をコードするヌクレオチド配列を含む、項目1~12のいずれか一項に記載の方法。 (項目14) 前記rAAVが、配列番号2に示されるポリペプチド配列をコードするヌクレオチド配列を含む、項目1~12のいずれか一項に記載の方法。 (項目15) 前記rAAVが、配列番号4に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有する前記scAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目1~14のいずれか一項に記載の方法。 (項目16) 前記rAAVが、前記配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目15に記載の方法。 (項目17) 前記rAAVが、tMCKプロモーターを含む、項目1~16のいずれか一項に記載の方法。 (項目18) 前記tMCKプロモーターが、配列番号3に示されるヌクレオチド配列を含む、項目1~16のいずれか一項に記載の方法。 (項目19) 前記rAAVが、配列番号5の5’逆位末端反復配列を含む、項目1~18のいずれか一項に記載の方法。 (項目20) 前記rAAVが、配列番号6の3’逆位末端反復配列を含む、項目1~19のいずれか一項に記載の方法。 (項目21) 前記rAAVが、配列番号7のポリA配列を含む、項目1~20のいずれか一項に記載の方法。 (項目22) 前記rAAVが、血清型AAVrh.74のものである、項目1~21のいずれか一項に記載の方法。 (項目23) 前記筋ジストロフィーが、肢帯型筋ジストロフィーである、項目1~22のいずれか一項に記載の方法。 (項目24) 前記筋ジストロフィーが、肢帯型筋ジストロフィー2D型(LGMD2D)である、項目1~23のいずれか一項に記載の方法。 (項目25) 前記対象が、肢帯型筋ジストロフィーに罹患しており、前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量で静脈内注入によって投与され、前記rAAVが、前記配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目1~24のいずれか一項に記載の方法。 (項目26) 前記対象の細胞における前記アルファ-サルコグリカン遺伝子発現のレベルが、前記rAAVの投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記rAAVの投与後に増加する、項目1~25のいずれか一項に記載の方法。 (項目27) 線維症が、前記rAAVの投与前と比較して、前記rAAVの投与後の前記対象において軽減する、項目1~26のいずれか一項に記載の方法。 (項目28) 前記対象における前記線維症、中心核形成、前記CKレベル、および/またはコラーゲン沈着が、前記rAAVの投与前と比較して、前記rAAVの投与後に減少する、項目1~26のいずれか一項に記載の方法。 (項目29) 前記対象の前記筋肉における比力、線維直径サイズ、および/または偏心収縮が、前記rAAVの投与前と比較して、前記rAAVの投与後に増加する、項目1~26のいずれか一項に記載の方法。 (項目30) 前記アルファ-サルコグリカン遺伝子発現が、ウエスタンブロットおよび/または免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目26に記載の方法。 (項目31) 配列番号4のヌクレオチド配列を含む前記scAAVrh74.tMCK.hSGCA構築物を対象に投与することを含む、細胞においてアルファ-サルコグリカン遺伝子を発現する、方法。 (項目32) 前記対象の前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検におけるウエスタンブロットでアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目31に記載の方法。 (項目33) 前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検における免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目31に記載の方法。 (項目34) 前記アルファ-サルコグリカン遺伝子の発現が、ゲノムDNAの1マイクログラム当たりのベクターゲノムの数を検出することによって前記対象において測定される、項目31に記載の方法。 (項目35) 血清CKレベルの減少を必要とする対象においてそれを行う方法であって、前記方法が、配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を前記対象に投与することを含む、方法。 (項目36) 対象の筋肉組織におけるアルファ-サルコグリカン陽性線維を増加させる方法であって、配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を前記対象に投与することを含む、方法。 (項目37) アルファ-サルコグリカンの発現の増加を必要とする対象においてそれを行う方法であって、有効量の配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を前記対象に投与することを含む、方法。 (項目38) 筋ジストロフィーの治療を必要とする対象においてそれを行うための組成物であって、前記組成物が、組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGAを、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.0×1012vg/kg~約5.0×1015vgの用量で含み、前記組成物が、全身投与経路用に製剤化される、組成物。 (項目39) 筋ジストロフィーの治療を必要とする対象においてそれを行うための組成物であって、前記組成物が、組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGAを、前記定量標準としての線形化されたDNAまたはプラスミドに基づいて、約1.85×1013vg/kgまたは7.41×1013vg/の用量で含み、前記組成物が、全身投与経路用に製剤化される、組成物。 (項目40) 組成物は、組換えアデノ随伴ウイルス(rAAV)を含み、前記rAAVが、配列番号4に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有するscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む。 (項目41) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量にある、項目38または40に記載の組成物。 (項目42) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg、約1×1014vg/kg、または約2×1014vg/kgの用量にある、項目38または40に記載の組成物。 (項目43) 前記対象の細胞におけるアルファ-サルコグリカン遺伝子発現のレベルが、前記組成物の投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記組成物の投与後に増加するか、または前記組成対象における血清CKレベルが、前記組成物の投与前の血清CKレベルと比較して、前記組成物の投与後に減少するか、または前記対象の筋肉組織におけるアルファ-サルコグリカン陽性線維の数が、前記組成物の投与前の前記アルファ-サルコグリカン陽性線維の数と比較して、前記組成物の投与後に増加する、項目38~42のいずれか一項に記載の組成物。 (項目44) 前記全身投与経路が、静脈内経路である、項目38~43のいずれか一項に記載の組成物。 (項目45) 前記組成物が、注射、注入、または移植によって投与される、項目38~44のいずれか一項に記載の組成物。 (項目46) 前記組成物が、注入による投与用に製剤化される、項目38~45のいずれか一項に記載の組成物。 (項目47) 前記組成物が、末梢四肢静脈を介する静脈内経路による投与用に製剤化される、項目38~46のいずれか一項に記載の組成物。 (項目48) 前記rAAVが、配列番号1に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有するヌクレオチド配列を含む、項目38~47のいずれか一項に記載の組成物。 (項目49) 前記rAAVが、配列番号1のヌクレオチド配列を含む、項目48に記載の組成物。 (項目50) 前記rAAVが、配列番号2に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるポリペプチド配列をコードするヌクレオチド配列を含む、項目38~49のいずれか一項に記載の組成物。 (項目51) 前記rAAVが、配列番号2に示されるポリペプチド配列をコードするヌクレオチド配列を含む、項目38~49のいずれか一項に記載の組成物。 (項目52) 前記rAAVが、配列番号4に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有する前記scAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目38~49のいずれか一項に記載の組成物。 (項目53) 前記rAAVが、配列番号4の前記scAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目52に記載の組成物。 (項目54) 前記rAAVが、tMCKプロモーターを含む、項目38~53のいずれか一項に記載の組成物。 (項目55) 前記tMCKプロモーターが、配列番号3に示されるヌクレオチド配列を含む、項目54に記載の組成物。 (項目56) 前記rAAVが、配列番号5の5’逆位末端反復配列を含む、項目38~55のいずれか一項に記載の組成物。 (項目57) 前記rAAVが、配列番号6の3’逆位末端反復配列を含む、項目38~56のいずれか一項に記載の組成物。 (項目58) 前記rAAVが、配列番号7のポリA配列を含む、項目38~57のいずれか一項に記載の組成物。 (項目59) 前記rAAVが、血清型AAVrh.74のものである、項目38~58のいずれか一項に記載の組成物。 (項目60) 前記筋ジストロフィーが、肢帯筋ジストロフィーである、項目38~59のいずれか一項に記載の組成物。 (項目61) 前記筋ジストロフィーが、肢帯型筋ジストロフィー2D型(LGMD2D)である、項目38~60のいずれか一項に記載の組成物。 (項目62) 前記対象が、肢帯型筋ジストロフィーに罹患しており、前記組成物が、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量での静脈内注入による投与用に製剤化され、前記rAAVが、配列番号4の前記scAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目38~61のいずれか一項に記載の組成物。 (項目63) 前記対象の細胞における前記アルファ-サルコグリカン遺伝子発現のレベルが、前記組成物の投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記組成物の投与後に増加する、項目38~62のいずれか一項に記載の組成物。 (項目64) 線維症が、前記組成物の投与前と比較して、前記組成物の投与後の前記対象において軽減する、項目38~63のいずれか一項に記載の組成物。 (項目65) 前記対象における線維症、中心核形成、前記CKレベル、および/またはコラーゲン沈着が、前記組成物の投与前と比較して、前記組成物の投与後に減少する、項目38~63のいずれか一項に記載の組成物。 (項目66) 前記対象の前記筋肉における比力、線維直径サイズ、および/または偏心収縮が、前記組成物の投与前と比較して、前記組成物の投与後に増加する、項目38~65のいずれか一項に記載の組成物。 (項目67) 前記アルファ-サルコグリカン遺伝子発現が、ウエスタンブロットおよび/または免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目63に記載の組成物。 (項目68) 細胞においてアルファ-サルコグリカン遺伝子を発現するための組成物であって、前記組成物が、配列番号4の前記scAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、組成物。 (項目69) 前記対象の前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検におけるウエスタンブロットでアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目68に記載の組成物。 (項目70) 前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検における免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目68に記載の組成物。 (項目71) 前記アルファ-サルコグリカン遺伝子の発現が、ゲノムDNAの1マイクログラム当たりのベクターゲノムの数を検出することによって前記対象において測定される、項目68に記載の組成物。 (項目72) 血清CKレベルの減少を必要とする対象においてそれを行うための組成物であって、前記配列番号4のヌクレオチド配列を含む前記scAAVrh74.tMCK.hSGCA構築物を含む、組成物。 (項目73) 前記配列番号4のヌクレオチド配列を含むscAAVrh74.tMCK.hSGCA構築物を含む、対象の筋肉組織におけるアルファ-サルコグリカン陽性線維を増加させるための、組成物。 (項目74) 配列番号4のヌクレオチド配列を含むscAAVrh74.tMCK.hSGCA構築物を含む、アルファ-サルコグリカンの発現の増加を必要とする対象においてそれを行うための、組成物。 (項目75) 筋ジストロフィーの治療を必要とする対象においてそれを行うための医薬の調製のための組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGA Aの使用であって、前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.0×1012vg/kg~約5.0×1015vg/kgの用量にあり、前記医薬が、全身投与経路用に製剤化される、使用。 (項目76) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約1.0×1012vg/kg~約2.0×1015vg/kg、約5×1012vg/kg~約1.0×1015vg/kg、約1.0×1013vg/kg~約5.0×1014vg/kg、約2.0×1013vg/kg~約3.0×1014vg/kg、または約5×1013vg/kg~約2×1014vg/kgの用量にある、項目75に記載の使用。 (項目77) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量にある、項目75に記載の使用。 (項目78) 前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg、約1×1014vg/kg、または約2×1014vg/kgの用量にある、項目75に記載の使用。 (項目79) 筋ジストロフィーの治療を必要とする対象においてそれを行うための医薬の調製のための組換えアデノ随伴ウイルス(rAAV)AAVrh74.tMCK.hSCGA Aの使用であって、前記rAAVが、前記定量標準としての線形化されたDNAまたはプラスミドに基づいて、約1.85×1013vg/kgまたは7.41×1013vg/kgの用量にあり、前記医薬が、全身投与経路用に製剤化される、使用。 (項目80) 前記対象の細胞におけるアルファ-サルコグリカン遺伝子発現のレベルが、前記医薬の投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記医薬の投与後に増加するか、または前記対象における血清CKレベルが、前記医薬の投与前の血清CKレベルと比較して、前記医薬の投与後に減少するか、または前記対象の筋肉組織におけるアルファ-サルコグリカン陽性線維の数が、前記医薬の投与前の前記アルファ-サルコグリカン陽性線維の数と比較して、rAAVの投与後に増加する、項目75~79のいずれか一項に記載の使用。 (項目81) 前記全身投与経路が、静脈内経路である、項目75~80のいずれか一項に記載の使用。 (項目82) 前記医薬が、注射、注入、または移植による投与用に製剤化される、項目75~81のいずれか一項に記載の使用。 (項目83) 前記医薬が、注入による投与用に製剤化される、項目75~82のいずれか一項に記載の使用。 (項目84) 前記医薬が、末梢四肢静脈を介する静脈内経路による投与用に製剤化される、項目75~83のいずれか一項に記載の使用。 (項目85) 前記rAAVが、配列番号1に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有するヌクレオチド配列を含む、項目75~84のいずれか一項に記載の使用。 (項目86) 前記rAAVが、配列番号1のヌクレオチド配列を含む、項目85に記載の使用。 (項目87) 前記rAAVが、配列番号2に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるポリペプチド配列をコードするヌクレオチド配列を含む、項目75~86のいずれか一項に記載の使用。 (項目88) 前記rAAVが、配列番号2に示されるポリペプチド配列をコードするヌクレオチド配列を含む、項目75~86のいずれか一項に記載の使用。 (項目89) 前記rAAVが、配列番号4に対する少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%の同一性を有するscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目75~86のいずれか一項に記載の使用。 (項目90) 前記rAAVが、配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目89に記載の使用。 (項目91) 前記rAAVが、tMCKプロモーターを含む、項目75~90のいずれか一項に記載の使用。 (項目92) 前記tMCKプロモーターが、配列番号3に示されるヌクレオチド配列を含む、項目91に記載の使用。 (項目93) 前記rAAVが、配列番号5の5’逆位末端反復配列を含む、項目75~92のいずれか一項に記載の使用。 (項目94) 前記rAAVが、配列番号6の3’逆位末端反復配列を含む、項目75~93のいずれか一項に記載の使用。 (項目95) 前記rAAVが、配列番号7ポリA配列を含む、項目73~94のいずれか一項に記載の使用。 (項目96) 前記rAAVが、血清型AAVrh.74のものである、項目73~95のいずれか一項に記載の使用。 (項目97) 前記筋ジストロフィーが、肢帯型筋ジストロフィーである、項目73~96のいずれか一項に記載の使用。 (項目98) 前記筋ジストロフィーが、肢帯型筋ジストロフィー2D型(LGMD2D)である、項目73~97のいずれか一項に記載の使用。 (項目99) 前記対象が、肢帯型筋ジストロフィーに罹患しており、前記医薬が、静脈内注入用に製剤化され、前記rAAVが、前記定量標準としての超らせんDNAまたはプラスミドに基づいて、約5×1013vg/kg~約2×1014vg/kgの用量にあり、前記rAAVが、前記配列番号4のscAAVrh74.tMCK.hSGCA構築物ヌクレオチド配列を含む、項目73~98のいずれか一項に記載の使用。 (項目100) 前記対象の細胞における前記アルファ-サルコグリカン遺伝子発現のレベルが、前記医薬の投与前の前記アルファ-サルコグリカン遺伝子発現のレベルと比較して、前記医薬の投与後に増加する、項目73~99のいずれか一項に記載の使用。 (項目101) 線維症が、前記医薬の投与前と比較して、前記医薬の投与後の前記対象において軽減する、項目73~100のいずれか一項に記載の使用。 (項目102) 前記対象における線維症、中心核形成、CKレベル、および/またはコラーゲン沈着が、前記医薬の投与前の前記線維症と比較して、前記医薬の投与後に減少する、項目73~100のいずれか一項に記載の使用。 (項目103) 前記対象の前記筋肉における比力、線維直径サイズ、および/または偏心収縮が、前記医薬の投与前と比較して、前記医薬の投与後に増加する、項目72~102のいずれか一項に記載の使用。 (項目104) 前記アルファ-サルコグリカン遺伝子発現が、ウエスタンブロットおよび/または免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目100に記載の使用。 (項目105) 細胞においてアルファ-サルコグリカン遺伝子を発現するための医薬の調製のためのscAAVrh74.tMCK.hSGCA構築物の使用であって、前記scAAVrh74.tMCK.hSGCA構築物が、配列番号4のヌクレオチド配列を含む、使用。 (項目106) 前記対象の前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検におけるウエスタンブロットでアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目105に記載の使用。 (項目107) 前記細胞における前記アルファ-サルコグリカン遺伝子の発現が、筋生検における免疫組織化学によってアルファ-サルコグリカンタンパク質レベルを測定することによって検出される、項目105に記載の使用。 (項目108) 前記アルファ-サルコグリカン遺伝子の発現が、ゲノムDNAの1マイクログラム当たりのベクターゲノムの数を検出することによって前記対象において測定される、項目105に記載の使用。 (項目109) 血清CKレベルの減少を必要とする対象においてそれを行うための医薬の調製のためのscAAVrh74.tMCK.hSGCA構築物の使用であって、前記scAAVrh74.tMCK.hSGCA構築物が、配列番号4のヌクレオチド配列を含む、使用。 (項目110) 対象の筋肉組織におけるアルファ-サルコグリカン陽性線維を増加させるための医薬の調製のためのscAAVrh74.tMCK.hSGCA構築物の使用であって、前記scAAVrh74.tMCK.hSGCA構築物が、配列番号4のヌクレオチド配列を含む、使用。 (項目111) アルファ-サルコグリカンの発現の増加を必要とする対象においてそれを行うための医薬の調製のためのscAAVrh74.tMCK.hSGCA構築物の使用であって、前記scAAVrh74.tMCK.hSGCA構築物が、配列番号4のヌクレオチド配列を含む、使用。 (項目112) 前記対象が、4~15歳であるヒト対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目113) 前記対象が、小児対象、青年対象、または若年成人対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目114) 前記対象が、4~15歳であり、両方の対立遺伝子において確認されたアルファ-サルコグリカン(SGCA)変異を有し、AAVrh74抗体に対して陰性であり、かつ/または40%超もしくは通常の100メートルの歩行試験を有した、ヒト対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目115) 前記対象が、中年成人または高齢対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目116) 前記対象が、25~55歳であるヒト対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目117) 前記対象が、50歳以上であるヒト対象である、項目1~111のいずれか一項に記載の方法、組成物、または使用。 (項目118) AAVベクタープラスミドを宿主細胞に移入することを含む、項目1~117のいずれか一項に記載の方法、組成物、または使用において投与された前記rAAVを生成する方法であって、前記AAVベクタープラスミドが、配列番号8に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるヌクレオチド配列を含む、方法。 (項目119) 前記AAVベクタープラスミドが、配列番号8のヌクレオチド配列を含む、項目118に記載の方法。 (項目120) 前記ベクタープラスミドが、配列番号1、4、または8に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるヌクレオチド配列を含む、項目118または119に記載の方法。 (項目121) 前記ベクタープラスミドが、配列番号1、4、または8のヌクレオチド配列を含む、項目118または119に記載の方法。 (項目122) パッケージングプラスミドおよび/またはヘルパーウイルスを前記宿主細胞に移入することをさらに含む、項目118~121のいずれか一項に記載の方法。 (項目123) パッケージング細胞が、安定に組み込まれたAAVcap遺伝子を含む、項目118~122のいずれか一項に記載の方法。 (項目124) 前記パッケージング細胞が、安定に組み込まれたAAVrep遺伝子を含む、項目118~123のいずれか一項に記載の方法。 (項目125) 配列番号1、4、または8に対して少なくとも90%、91%、92%、93%、94%、95%、96%、97%、98%、または99%同一であるヌクレオチド配列を含むAAVベクタープラスミドを含む、宿主細胞。 (項目126) 前記AAVベクタープラスミドが、配列番号1、4、または8のヌクレオチド配列を含む、項目125に記載の宿主細胞。
Smart Images

Figure 2024156816000011 
Figure 2024156816000012 
Figure 2024156816000013
Abstract
Description
[Technical field]
[0001] Related Applications This application claims priority to U.S. Provisional Application No. 62 / 889,749, filed August 21, 2019, U.S. Provisional Application No. 63 / 014,934, filed April 24, 2020, and U.S. Patent Application No. 63 / 022,843, filed May 11, 2020, all of which are incorporated by reference in their entireties herein.
[0002] Described herein are therapeutic vectors, such as AAV vectors that express alpha-sarcoglycan, and methods of using these vectors to treat limb-girdle muscular dystrophies, such as LGMD2D.
[0003] Incorporation by reference of sequence listing This application contains, as a separate part of the disclosure, a sequence listing in computer readable format (Filename: 54652_SeqListing.txt, 18,768 bytes, ASCII text file, created on August 17, 2020), which is incorporated by reference in its entirety herein. [Background technology]
[0004] Muscular dystrophies (MD) are a group of genetic disorders characterized by progressive weakening and degeneration of the skeletal muscles that control movement. Some forms of MD have an onset in infancy or childhood, whereas others may not appear until middle age or later. The disorders differ in the distribution and degree of muscle weakness (some forms of MD also affect the heart muscle), age at onset, rate of progression, and mode of inheritance.
[0005] One group of MDs are the limb-girdle muscular dystrophies (LGMDs). LGMDs are rare conditions and vary in symptoms from person to person with regard to age of onset, areas of muscle weakness, cardiac and respiratory involvement, rate of progression, and severity. LGMDs may begin in childhood, adolescence, young adulthood, or later. Both genders are affected equally. LGMDs cause weakness in the shoulders and pelvic girdle, and nearby muscles in the upper limbs and arms may also weaken over time. Leg weakness often precedes arm weakness. Facial muscles are not usually affected. As the condition progresses, people may have problems walking and may need to use a wheelchair over time. Shoulder and arm muscles are involved, which can lead to difficulty raising the arms above the head or lifting objects. Depending on the type of LGMD, cardiac and respiratory muscles may be involved.
[0006] Specialist tests for LGMD are now available through the National Commissioning Group (NCG), the national scheme for diagnosis.
[0007] LGMD subtype 2D (LGMD2D), often referred to as α-sarcoglycanopathy, is an autosomal recessive disease caused by mutations in the alpha-sarcoglycan gene (SGCA; α-sarcoglycan), resulting in complete or reduced loss of functional protein accompanied by loss of other structural components of the dystrophin-associated protein complex. In particular, loss of alpha-sarcoglycan protein causes progressive muscular dystrophy with reduced muscle function, with onset between 3 and 8 years of age. Symptoms include delayed gait, proximal muscle weakness caused by fatty replacement and fibrosis, elevated creatine kinase, scoliosis, and joint contractures. The debilitating disease often leads to wheelchair dependency and death due to respiratory failure. Thus, there remains a need for treatment of LGMD2D. Summary of the Invention [Means for solving the problem]
[0008] Described herein is a method for treating muscular dystrophy in a subject in need thereof, comprising administering a recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA, the rAAV being administered using a systemic route to a subject in need thereof, the subject receiving the treatment being able to deliver approximately 1.0×10 mAb of muscular dystrophy, based on supercoiled DNA or plasmid as a quantification standard. 12 vg / kg ~ approx. 5.0×10 15 In one aspect, the disclosure relates to rAAVs expressing the alpha-sarcoglycan gene and methods of delivering alpha-sarcoglycan to muscle to reduce and / or prevent fibrosis and / or increase muscle strength and / or treat alpha-sarcoglycanopathy in subjects suffering from muscular dystrophy.
[0009] In one aspect, described herein is a recombinant AAV (rAAV) comprising a polynucleotide sequence encoding an alpha-sarcoglycan protein. In some embodiments, the polynucleotide sequence comprises a sequence that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 1 and encodes a protein that retains alpha-sarcoglycan activity. In some embodiments, the polynucleotide sequence comprises the nucleotide sequence shown in SEQ ID NO: 1. In some embodiments, the polynucleotide encodes a protein that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identical to the nucleotide sequence set forth in SEQ ID NO: 2. In another embodiment, the polynucleotide encodes a protein comprising the amino acid sequence set forth in SEQ ID NO:2.
[0010] In some embodiments, the rAAV comprises a nucleotide sequence comprising a tMCK promoter. For example, the tMCK promoter comprises the nucleotide sequence shown in SEQ ID NO: 3. In addition, the rAAV comprises a 5' inverted terminal repeat sequence of SEQ ID NO: 5 and / or a 3' inverted terminal repeat sequence of SEQ ID NO: 6. In some embodiments, the rAAV comprises a polyA sequence of SEQ ID NO: 7. In one embodiment, the disclosed rAAV is of serotype AAVrh.74.
[0011] In one embodiment, the polynucleotide comprises a nucleotide sequence that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to SEQ ID NO: 4. In one embodiment, the polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO:4.
[0012] The present disclosure provides a method of treating muscular dystrophy in a subject in need thereof, comprising administering any of the rAAVs disclosed herein, wherein the rAAV is administered by a systemic route. In particular, in any of the disclosed methods, the rAAV is AAVrh74.tMCK.hSCGA, and the rAAV is administered using a systemic administration route.
[0013] In any of the disclosed methods, the rAAV is expressed at approximately 1.0×10 mAb, based on supercoiled DNA or plasmid as a quantitative standard. 12 vg / kg ~ approx. 5.0×10 15 For example, rAAV is administered at a dose of approximately 1.0×10 vg / kg, based on supercoiled DNA or plasmid as a quantitative standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 2.0×1013 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5 × 10 13 vg / kg ~ approx. 2×10 14 vg / kg, or rAAV is administered at a dose of approximately 5×10 13 vg / kg, approximately 6×10 13 vg / kg, approximately 7×10 13 vg / kg, approx. 8×10 13 vg / kg, approx. 9×10 13 vg / kg, approximately 1×10 14 vg / kg, 2 × 10 14 vg / kg, approx. 3×10 14 vg / kg, approx. 4×10 14 vg / kg, or approximately 5 × 10 14 The drug is administered at a dose of 100 mg / kg.
[0014] In another embodiment, in any of the disclosed methods, the rAAV is expressed at about 1.85×10 mAb, based on linearized DNA or plasmid as a quantification standard. 13 vg / kg or 7.41 × 10 13 For example, rAAV is administered at a dose of approximately 1.0×10 vg / kg, based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.5×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.6×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.8×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.2×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.4×10 13 vg / kg ~ approx. 7.4×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13vg / kg, or approximately 1.8 × 10 13 vg / kg ~ approx. 8.0×10 13 The drug is administered at a dose of 100 mg / kg.
[0015] In addition, in any of the disclosed methods, the systemic administration route is an intravenous route.For example, in any of the disclosed methods, rAAV is administered by injection, infusion or implantation.In some embodiments, rAAV is administered by intravenous route via peripheral limb vein.
[0016] In any of the disclosed methods, the muscular dystrophy is limb-girdle muscular dystrophy. For example, the muscular dystrophy is limb-girdle muscular dystrophy type 2D (LGMD2D).
[0017] In an exemplary embodiment, a method of treating muscular dystrophy includes administering rAAV to a subject suffering from limb-girdle muscular dystrophy, the rAAV being approximately 5×10 13 vg / kg ~ approx. 2×10 14 The rAAV was administered by intravenous infusion at a dose of 1000 mg / kg, and the rAAV contained the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0018] In an exemplary embodiment, the disclosure provides a method for treating muscular dystrophy in a subject in need thereof, the method comprising administering to the subject an rAAV, the subject suffering from limb-girdle muscular dystrophy, the rAAV being at about 5×10 13 vg / kg ~ approx. 2×10 14vg / kg, and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. For example, in these methods, the level of alpha-sarcoglycan gene expression in cells of the subject is increased after administration of the rAAV compared to the level of alpha-sarcoglycan gene expression before administration of the rAAV.
[0019] In any of the disclosed methods, the level of alpha-sarcoglycan gene expression in cells of the subject is increased after administration of the rAAV compared to the level of alpha-sarcoglycan gene expression before administration of the rAAV, and / or serum CK levels in the subject are decreased after administration of the rAAV compared to serum CK levels before administration of the rAAV, and / or locomotor activity and specific force production are increased, fibrosis is reduced, resistance to contraction-induced damage of the tibialis anterior muscle is increased, and / or muscle tissue of the subject is improved. The number of alpha-sarcoglycan positive fibers in the tissue is increased after administration of rAAV compared to the number of alpha-sarcoglycan positive fibers before administration of rAAV, or fibrosis is reduced in the subject after administration of rAAV compared to before administration of rAAV, and / or fibrosis is reduced in the subject after administration of rAAV compared to before administration of rAAV, and / or specific force, fiber diameter size, and / or eccentric contraction in the subject's muscle is increased after administration of rAAV compared to before administration of rAAV.
[0020] In some embodiments, alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry.
[0021] In another aspect, the present disclosure provides a method for expressing the alpha-sarcoglycan gene in a cell, comprising administering to a subject any of the disclosed rAAVs. For example, the present disclosure provides a method for expressing the alpha-sarcoglycan gene in a cell, comprising administering to a subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In addition, in any of the methods, the expression of the alpha-sarcoglycan gene in a cell is detected by measuring the alpha-sarcoglycan protein level by Western blot in a muscle biopsy. Alternatively, in any of the methods, the expression of the alpha-sarcoglycan gene in a cell is detected by measuring the alpha-sarcoglycan protein level by immunohistochemistry in a muscle biopsy. In other embodiments, the expression of the alpha-sarcoglycan gene is measured in a subject by detecting the number of vector genomes per microgram of genomic DNA.
[0022] The present disclosure provides a method of reducing serum CK levels in a subject in need thereof, comprising administering to the subject any of the disclosed rAAVs. For example, the present disclosure provides a method of reducing serum CK levels in a subject in need thereof, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0023] In another aspect, the present disclosure provides a method of increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject, comprising administering to the subject any of the disclosed rAAVs. For example, the present disclosure provides a method of increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject in need thereof, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0024] The present disclosure also provides a method of increasing the expression of alpha-sarcoglycan in a subject in need thereof, comprising administering to the subject any of the disclosed rAAVs. For example, the present disclosure provides a method of increasing the expression of alpha-sarcoglycan in a subject in need thereof, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In addition, in any of the disclosed methods, the expression of the alpha-sarcoglycan gene in the cells of the subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. Alternatively, in any of the methods, the expression of the alpha-sarcoglycan gene in the cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in a muscle biopsy. In other embodiments, the expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA.
[0025] The present disclosure provides compositions for treating muscular dystrophy in a subject in need thereof, the compositions comprising any of the rAAVs disclosed herein, the compositions being formulated for administration by a systemic route. In particular, in any of the compositions, the rAAV is AAVrh74.tMCK.hSCGA.
[0026] Any of the disclosed compositions may be used to measure approximately 1.0×10 12 vg / kg ~ approx. 5.0×10 15 For example, rAAV may be administered at a dose of approximately 1.0×10 vg / kg, based on supercoiled DNA or plasmid as a quantitative standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14vg / kg, approx. 2.0×10 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5 × 10 13 vg / kg ~ approx. 2×10 14 The dose of rAAV is approximately 5 × 10 13 vg / kg, approximately 6×10 13 vg / kg, approximately 7×10 13 vg / kg, approx. 8×10 13 vg / kg, approx. 9×10 13 vg / kg, approximately 1×10 14 vg / kg, approx. 2×10 14 vg / kg, approx. 3×10 14 vg / kg, approx. 4×10 14 vg / kg, or approximately 5 × 10 14 in vg / kg doses.
[0027] In another embodiment, in any of the disclosed compositions, the rAAV is expressed at about 1.85×10 13 vg / kg or approximately 7.41 × 10 13 For example, rAAV is administered at a dose of approximately 1.0×10 vg / kg, based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.5×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.6×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.8×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.2×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.4×10 13 vg / kg ~ approx. 7.4×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13vg / kg, or approximately 1.8 × 10 13 vg / kg ~ approx. 8.0×10 13 The drug is administered at a dose of 100 mg / kg.
[0028] In addition, any of the disclosed compositions are formulated for administration via an intravenous route, such as a composition formulated for administration via injection, infusion, or implantation, hi some embodiments, the disclosed compositions are formulated for administration via an intravenous route via a peripheral limb vein.
[0029] Any of the disclosed compositions are for the treatment of limb-girdle muscular dystrophy, such as limb-girdle muscular dystrophy type 2D (LGMD2D).
[0030] In an exemplary embodiment, the disclosure provides a composition for treating a subject suffering from limb-girdle muscular dystrophy, the composition comprising a 5×10 mAb or ... 13 vg / kg ~ approx. 2×10 14 The composition comprises a dose of rAAV in vg / kg, the composition is formulated for administration by intravenous infusion, and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0031] In addition, the disclosure provides a composition for treating limb-girdle muscular dystrophy in a subject in need thereof, the composition comprising a 5×10 mAb or ... 13 vg / kg ~ approx. 2×10 14 The composition comprises a dose of rAAV in vg / kg, the composition is formulated for administration by intravenous infusion, and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. For example, administration of the composition increases the level of alpha-sarcoglycan gene expression in cells of the subject compared to the level of alpha-sarcoglycan gene expression prior to administration of the composition.
[0032] Additionally, administration of any of the disclosed compositions increases the level of alpha-sarcoglycan gene expression in the subject's cells compared to the level of alpha-sarcoglycan gene expression prior to administration of the composition, and / or administration of the disclosed compositions decreases serum CK levels in the subject compared to serum CK levels prior to administration of the composition, and / or locomotor activity and specific force production are increased, fibrosis is reduced, and resistance to contraction-induced damage of the tibialis anterior muscle is increased, and / or administration of the composition increases the number of alpha-sarcoglycan positive fibers in the subject's muscle tissue compared to the number of alpha-sarcoglycan positive fibers prior to administration of the composition, and / or administration of the composition reduces fibrosis in the subject compared to prior to administration of rAAV, and / or the composition reduces fibrosis compared to prior to administration of the composition, or administration of the composition increases specific force, fiber diameter size, and / or eccentric contraction in the subject's muscles compared to prior to administration of the composition. In some embodiments, alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry.
[0033] In another aspect, the present disclosure provides a composition for expressing alpha-sarcoglycan gene in a cell, the composition comprising any of the disclosed rAAVs. For example, the present disclosure provides a composition for expressing alpha-sarcoglycan gene in a cell, the composition comprising the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In addition, in any of the compositions, the expression of alpha-sarcoglycan gene in a cell of a subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. Alternatively, in any of the methods, the expression of alpha-sarcoglycan gene in a cell is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in a muscle biopsy. In other embodiments, the expression of alpha-sarcoglycan gene is measured in a subject by detecting the number of vector genomes per microgram of genomic DNA.
[0034] The present disclosure provides a composition for reducing serum CK levels in a subject in need thereof, the composition comprising any of the disclosed rAAVs. For example, the present disclosure provides a composition for reducing serum CK levels in a subject in need thereof, the composition comprising the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0035] In another aspect, the present disclosure provides a composition for increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject, the composition comprising any of the disclosed rAAVs. For example, the present disclosure provides a composition for increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject, the composition comprising the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0036] The present disclosure also provides a composition for increasing the expression of alpha-sarcoglycan in a subject in need thereof, the composition comprising any of the disclosed rAAVs. For example, the present disclosure provides a composition for increasing the expression of alpha-sarcoglycan in a subject in need thereof, the composition comprising the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In addition, after administration of any of the disclosed compositions, expression of the alpha-sarcoglycan gene in cells of the subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in muscle biopsy. Alternatively, after administration of any of the disclosed compositions, expression of the alpha-sarcoglycan gene in cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in muscle biopsy. In other embodiments, after administration of any of the disclosed compositions, expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA.
[0037] The present disclosure provides the use of any of the disclosed rAAVs for the preparation of a medicament for treating muscular dystrophy in a subject in need thereof, the medicament being formulated for administration by a systemic route. In particular, the present disclosure provides the use of AAVrh74.tMCK.hSCGA for the preparation of a medicament for treating muscular dystrophy, the medicament being formulated for administration by a systemic route.
[0038] In any of the disclosed uses, the pharmaceutical is administered at a concentration of about 1.0×10 based on supercoiled DNA or plasmid as a quantitative standard. 12 vg / kg ~ approx. 5.0×10 15 For example, rAAV may be administered at a dose of approximately 1.0×10 vg / kg, based on supercoiled DNA or plasmid as a quantitative standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 2.0×10 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5 × 10 13 vg / kg ~ approx. 2×10 14 The dose of rAAV is approximately 5 × 10 13 vg / kg, approximately 6×10 13 vg / kg, approximately 7×10 13 vg / kg, approx. 8×10 13 vg / kg, approx. 9×10 13 vg / kg, approximately 1×10 14 vg / kg, approx. 2×10 14 vg / kg, approx. 3×10 14 vg / kg, approx. 4×10 14 vg / kg, or approximately 5 × 10 14 in vg / kg.
[0039] In another embodiment, in any of the disclosed uses, the medicament is a medicament having a concentration of about 1.85×10 based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg or 7.41 × 10 13 For example, the pharmaceutical may contain a dose of rAAV of about 1.0×10 based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.5×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.6×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.8×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.2×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.4×10 13 vg / kg ~ approx. 7.4×10 13 vg / kg, approximately 1.9×1013 vg / kg ~ approx. 7.5×10 13 vg / kg, or approximately 1.8 × 10 13 vg / kg ~ approx. 8.0×10 13 vg / kg dose of rAAV.
[0040] In addition, in any of the disclosed uses, the medicament is formulated for administration by intravenous route.For example, in any of the disclosed uses, the medicament is formulated for administration by injection, infusion or implantation.In some embodiments, the medicament is formulated for administration by intravenous route via peripheral limb vein.
[0041] In any of the disclosed uses, the medicament is for the treatment of limb-girdle muscular dystrophy, such as limb-girdle muscular dystrophy type 2D (LGMD2D).
[0042] In an exemplary embodiment, the disclosure provides a use of rAAV for the preparation of a medicament for treating limb-girdle muscular dystrophy, the medicament being formulated for administration by intravenous infusion, the rAAV being approximately 5×10 13 vg / kg ~ approx. 2×10 14 vg / kg, and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. For example, administration of the medicament to a subject in need thereof results in increased alpha-sarcoglycan gene expression in cells of the subject compared to the level of alpha-sarcoglycan gene expression prior to administration of the rAAV.
[0043] In any of the disclosed uses, administration of the pharmaceutical to a subject in need thereof results in an increase in the level of alpha-sarcoglycan gene expression in the subject's cells compared to the level of alpha-sarcoglycan gene expression before administration of the pharmaceutical, and / or administration of the pharmaceutical to a subject results in a decrease in serum CK levels in the subject compared to the serum CK levels before administration of the pharmaceutical, and / or locomotor activity and specific force production are increased, fibrosis is reduced, and resistance to contraction-induced damage of the tibialis anterior muscle is increased, and / or administration of an agent to a subject results in an increase in the number of alpha-sarcoglycan positive fibers in the subject's muscle tissue compared to the number of alpha-sarcoglycan positive fibers before administration of the pharmaceutical, and / or administration of the pharmaceutical to a subject in need thereof results in a reduction in fibrosis in the subject compared to before administration of the pharmaceutical, and / or administration of the pharmaceutical results in an increase in specific force, fiber diameter size, and / or eccentric contraction in the subject's muscle compared to before administration of the pharmaceutical. In some embodiments, alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry.
[0044] In another aspect, the present disclosure provides the use of any of the disclosed rAAVs for the preparation of a medicament for expressing the alpha-sarcoglycan gene in a cell in a subject in need thereof. For example, the present disclosure provides the use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for expressing the alpha-sarcoglycan gene in a cell in a subject in need thereof, the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO: 4. In addition, in any of the uses, the expression of the alpha-sarcoglycan gene in a cell of the subject is detected by measuring the alpha-sarcoglycan protein level by Western blot in a muscle biopsy. Alternatively, in any of the uses, the expression of the alpha-sarcoglycan gene in a cell is detected by measuring the alpha-sarcoglycan protein level by immunohistochemistry in a muscle biopsy. In other embodiments, the expression of the alpha-sarcoglycan gene is measured in a subject by detecting the number of vector genomes per microgram of genomic DNA.
[0045] The present disclosure provides for the use of any of the disclosed rAAVs for the preparation of a medicament for reducing serum CK levels in a subject in need thereof. For example, the present disclosure provides for the use of a scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for reducing serum CK levels in a subject in need thereof, the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4.
[0046] In another aspect, the present disclosure provides the use of any of the disclosed rAAVs for the preparation of a medicament for increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject. For example, the present disclosure provides the use of a scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for increasing alpha-sarcoglycan positive fibers in muscle tissue of a subject, the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4.
[0047] The present disclosure also provides the use of any of the disclosed rAAVs for the preparation of a medicament for increasing expression of alpha-sarcoglycan in a subject in need thereof. For example, the present disclosure provides the use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for increasing expression of alpha-sarcoglycan in a subject in need thereof, the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO: 4. Additionally, in any of the disclosed uses, the expression of the alpha-sarcoglycan gene in cells of a subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. Alternatively, in any of the disclosed uses, the expression of the alpha-sarcoglycan gene in cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in a muscle biopsy. In other embodiments, the expression of the alpha-sarcoglycan gene is measured in a subject by detecting the number of vector genomes per microgram of genomic DNA.
[0048] In any of the disclosed methods, compositions, or uses, the subject is a human subject between 4 and 15 years of age, or between 25 and 55 years of age, or over 50 years of age.
[0049] In any of the disclosed methods, compositions, or uses, the subject is a pediatric subject, an adolescent subject, or a young adult subject. Alternatively, the subject is a middle-aged adult or an elderly subject.
[0050] For example, in any of the disclosed methods, compositions, or uses, the subject is a human subject who is 4-15 years of age, has a confirmed alpha-sarcoglycan (SGCA) mutation in both alleles, is negative for AAVrh74 antibodies, and / or has a 100 meter walk test greater than 40% or normal.
[0051] In another aspect, the disclosure provides a method of generating a rAAV administered by any of the disclosed methods, compositions, or uses, comprising transferring an AAV vector plasmid into a host cell, wherein the AAV vector plasmid comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 8. For example, the AAV vector plasmid comprises the nucleotide sequence of SEQ ID NO: 8. In some embodiments, the vector plasmid comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 8, or the vector plasmid comprises the nucleotide sequence of SEQ ID NO: 1, 4, or 8.
[0052] In any of the disclosed methods of producing rAAV, the method further comprises transferring a packaging plasmid and / or a helper virus into the host cell. In addition, in any of the disclosed methods of producing rAAV, the packaging cell contains a stably integrated AAV cap gene and / or the packaging cell contains a stably integrated AAV rep gene.
[0053] In another aspect, the disclosure provides a host cell comprising an AAV vector plasmid comprising a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1, 4, or 8. For example, the host cell comprises an AAV vector plasmid comprising the nucleotide sequence of SEQ ID NO:1, 4, or 8. In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A method of treating muscular dystrophy in a subject in need thereof, comprising administering recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA, wherein the rAAV is administered in a dose of about 1.0×10 based on supercoiled DNA or plasmid as a quantification standard using a systemic route of administration.12 vg / kg ~ approx. 5.0×10 15 The method is administered at a dose of 100 mg / kg. (Item 2) The rAAV is about 1.0×10 based on supercoiled DNA or plasmid as the quantification standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 2.0×10 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5 × 10 13 vg / kg ~ approx. 2×10 14 The method of claim 1, wherein the therapeutic agent is administered at a dose of 0.05 mg / kg. (Item 3) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg ~ approx. 2×10 14 The method of claim 1, wherein the therapeutic agent is administered at a dose of 0.05 mg / kg. (Item 4) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg, approximately 1×10 14 vg / kg, or approximately 2 × 10 14 The method of claim 1, wherein the therapeutic agent is administered at a dose of 0.05 mg / kg. (Item 5) 1. A method of treating muscular dystrophy in a subject in need thereof, comprising administering recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA, wherein the rAAV is administered using a systemic route and delivers approximately 1.85×10 13 vg / kg ~ approx. 7.41×10 13 The method is administered at a dose of 100 mg / kg. (Item 6) The method of any one of items 1 to 5, wherein the level of alpha-sarcoglycan gene expression in the subject's cells is increased after administration of the rAAV compared to the level of alpha-sarcoglycan gene expression before administration of the rAAV, the serum CK level in the subject is decreased after administration of the rAAV compared to the serum CK level before administration of the rAAV, locomotor activity and specific force production are increased, fibrosis is reduced, resistance to contraction-induced damage of the tibialis anterior muscle is increased, and / or the number of alpha-sarcoglycan-positive fibers in the subject's muscle tissue is increased after administration of the rAAV compared to the number of alpha-sarcoglycan-positive fibers before administration of the rAAV. (Item 7) 7. The method according to any one of items 1 to 6, wherein the systemic administration route is an intravenous route. (Item 8) 8. The method of any one of items 1 to 7, wherein the rAAV is administered by injection, infusion or implantation. (Item 9) 9. The method of any one of items 1 to 8, wherein the rAAV is administered by injection. (Item 10) 10. The method of any one of items 1 to 9, wherein the rAAV is administered by an intravenous route via a peripheral limb vein. (Item 11) 11. The method of any one of items 1 to 10, wherein the rAAV comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1. (Item 12) The method of claim 11, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO:1. (Item 13) 13. The method of any one of items 1 to 12, wherein the rAAV comprises a nucleotide sequence encoding a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:2. (Item 14) 13. The method of any one of items 1 to 12, wherein the rAAV comprises a nucleotide sequence encoding the polypeptide sequence shown in SEQ ID NO:2. (Item 15) The method of any one of items 1 to 14, wherein the rAAV comprises a scAAVrh74.tMCK.hSGCA construct nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:4. (Item 16) The method of claim 15, wherein the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 17) 17. The method of any one of items 1 to 16, wherein the rAAV comprises a tMCK promoter. (Item 18) 17. The method according to any one of items 1 to 16, wherein the tMCK promoter comprises the nucleotide sequence shown in SEQ ID NO:3. (Item 19) 19. The method of any one of items 1 to 18, wherein the rAAV comprises the 5' inverted terminal repeat of SEQ ID NO:5. (Item 20) 20. The method of any one of items 1 to 19, wherein the rAAV comprises a 3' inverted terminal repeat of SEQ ID NO:6. (Item 21) 21. The method according to any one of items 1 to 20, wherein the rAAV comprises a polyA sequence of SEQ ID NO: 7. (Item 22) 22. The method of any one of items 1 to 21, wherein the rAAV is of the serotype AAVrh.74. (Item 23) 23. The method according to any one of items 1 to 22, wherein the muscular dystrophy is limb-girdle muscular dystrophy. (Item 24) 24. The method according to any one of items 1 to 23, wherein the muscular dystrophy is limb-girdle muscular dystrophy type 2D (LGMD2D). (Item 25) The subject is afflicted with limb-girdle muscular dystrophy, and the rAAV is administered at a concentration of about 5×10 based on the supercoiled DNA or plasmid as the quantitative standard. 13 vg / kg ~ approx. 2×10 14 25. The method of any one of items 1 to 24, wherein the rAAV is administered by intravenous infusion at a dose of 1000 ng / kg, and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. (Item 26) 26. The method of any one of items 1 to 25, wherein the level of alpha-sarcoglycan gene expression in the subject's cells is increased after administration of the rAAV compared to the level of alpha-sarcoglycan gene expression before administration of the rAAV. (Item 27) 27. The method of any one of items 1 to 26, wherein fibrosis is reduced in the subject after administration of the rAAV compared to before administration of the rAAV. (Item 28) 27. The method of any one of items 1 to 26, wherein the fibrosis, central nucleation, CK levels, and / or collagen deposition in the subject is reduced after administration of the rAAV compared to before administration of the rAAV. (Item 29) 27. The method of any one of items 1 to 26, wherein the specific force, fiber diameter size, and / or eccentric contraction in the muscle of the subject is increased after administration of the rAAV compared to before administration of the rAAV. (Item 30) 27. The method of claim 26, wherein the alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry. (Item 31) A method for expressing an alpha-sarcoglycan gene in a cell, comprising administering to a subject the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4. (Item 32) The method of claim 31, wherein expression of the alpha-sarcoglycan gene in the cells of the subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. (Item 33) 32. The method of claim 31, wherein expression of the alpha-sarcoglycan gene in the cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in a muscle biopsy. (Item 34) 32. The method of claim 31, wherein expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA. (Item 35) A method for reducing serum CK levels in a subject in need thereof, said method comprising administering to said subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 36) A method for increasing alpha-sarcoglycan positive fibers in a subject's muscle tissue, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 37) A method for increasing expression of alpha-sarcoglycan in a subject in need thereof, comprising administering to the subject an effective amount of the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 38) 1. A composition for treating muscular dystrophy in a subject in need thereof, said composition comprising recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA in an amount of about 1.0×10 12 vg / kg ~ approx. 5.0×10 15 vg, and wherein the composition is formulated for systemic administration. (Item 39) 1. A composition for treating muscular dystrophy in a subject in need thereof, the composition comprising: a recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA in an amount of about 1.85×10 based on linearized DNA or plasmid as the quantitative standard; 13 vg / kg or 7.41 × 10 13 vg / g, and wherein the composition is formulated for systemic administration. (Item 40) The composition comprises a recombinant adeno-associated virus (rAAV), wherein the rAAV comprises a scAAVrh74.tMCK.hSGCA construct nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:4. (Item 41) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg ~ approx. 2×10 14 41. The composition according to item 38 or 40, in a dose of 0.1 vg / kg. (Item 42) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg, approximately 1×10 14 vg / kg, or approximately 2 × 10 14 41. The composition according to item 38 or 40, in a dose of 0.1 vg / kg. (Item 43) The composition according to any one of items 38 to 42, wherein the level of alpha-sarcoglycan gene expression in the cells of the subject is increased after administration of the composition compared to the level of alpha-sarcoglycan gene expression before administration of the composition, or the serum CK level in the subject is decreased after administration of the composition compared to the serum CK level before administration of the composition, or the number of alpha-sarcoglycan-positive fibers in the muscle tissue of the subject is increased after administration of the composition compared to the number of alpha-sarcoglycan-positive fibers before administration of the composition. (Item 44) 44. The composition according to any one of items 38 to 43, wherein the systemic administration route is an intravenous route. (Item 45) 45. The composition according to any one of items 38 to 44, wherein the composition is administered by injection, infusion, or implantation. (Item 46) 46. The composition of any one of items 38 to 45, wherein the composition is formulated for administration by injection. (Item 47) 47. The composition according to any one of items 38 to 46, wherein the composition is formulated for administration by intravenous route via a peripheral limb vein. (Item 48) 48. The composition of any one of items 38-47, wherein the rAAV comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1. (Item 49) The composition of claim 48, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO:1. (Item 50) 50. The composition of any one of items 38-49, wherein the rAAV comprises a nucleotide sequence encoding a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:2. (Item 51) 50. The composition of any one of items 38 to 49, wherein the rAAV comprises a nucleotide sequence encoding the polypeptide sequence shown in SEQ ID NO:2. (Item 52) The composition of any one of items 38 to 49, wherein the rAAV comprises a scAAVrh74.tMCK.hSGCA construct nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:4. (Item 53) The composition of claim 52, wherein the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 54) 54. The composition of any one of items 38 to 53, wherein the rAAV comprises a tMCK promoter. (Item 55) 55. The composition of claim 54, wherein the tMCK promoter comprises the nucleotide sequence set forth in SEQ ID NO:3. (Item 56) 56. The composition of any one of items 38 to 55, wherein the rAAV comprises a 5' inverted terminal repeat of SEQ ID NO:5. (Item 57) 57. The composition of any one of items 38 to 56, wherein the rAAV comprises a 3' inverted terminal repeat of SEQ ID NO:6. (Item 58) 58. The composition of any one of items 38 to 57, wherein the rAAV comprises a polyA sequence of SEQ ID NO: 7. (Item 59) 59. The composition of any one of items 38 to 58, wherein the rAAV is of the serotype AAVrh.74. (Item 60) 60. The composition according to any one of items 38 to 59, wherein the muscular dystrophy is limb-girdle muscular dystrophy. (Item 61) 61. The composition according to any one of items 38 to 60, wherein the muscular dystrophy is limb-girdle muscular dystrophy type 2D (LGMD2D). (Item 62) The subject is afflicted with limb-girdle muscular dystrophy, and the composition is administered at a concentration of about 5×10 based on supercoiled DNA or plasmid as the quantitative standard. 13 vg / kg ~ approx. 2×10 14 62. The composition of any one of items 38 to 61, wherein the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4, and is formulated for administration by intravenous infusion at a dose of 1000 mg / kg. (Item 63) 63. The composition of any one of items 38 to 62, wherein the level of alpha-sarcoglycan gene expression in the cells of the subject is increased after administration of the composition compared to the level of alpha-sarcoglycan gene expression before administration of the composition. (Item 64) 64. The composition of any one of items 38 to 63, wherein fibrosis is reduced in the subject after administration of the composition compared to before administration of the composition. (Item 65) 64. The composition according to any one of items 38 to 63, wherein fibrosis, central nucleation, the CK level, and / or collagen deposition in the subject is reduced after administration of the composition compared to before administration of the composition. (Item 66) 66. The composition of any one of items 38 to 65, wherein specific strength, fiber diameter size, and / or eccentric contraction in the muscle of the subject is increased after administration of the composition compared to before administration of the composition. (Item 67) The composition of item 63, wherein the alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry. (Item 68) A composition for expressing an alpha-sarcoglycan gene in a cell, said composition comprising the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 69) The composition of item 68, wherein expression of the alpha-sarcoglycan gene in the cells of the subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. (Item 70) 69. The composition of claim 68, wherein expression of the alpha-sarcoglycan gene in the cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in a muscle biopsy. (Item 71) 69. The composition of claim 68, wherein expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA. (Item 72) A composition for reducing serum CK levels in a subject in need thereof, comprising the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4. (Item 73) A composition for increasing alpha-sarcoglycan positive fibers in a subject's muscle tissue, comprising the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4. (Item 74) A composition for increasing expression of alpha-sarcoglycan in a subject in need thereof, comprising the scAAVrh74.tMCK.hSGCA construct comprising the nucleotide sequence of SEQ ID NO:4. (Item 75) 1. Use of a recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA A for the preparation of a medicament for treating muscular dystrophy in a subject in need thereof, wherein said rAAV is capable of measuring approximately 1.0×10 12 vg / kg ~ approx. 5.0×10 15 vg / kg and said medicament is formulated for systemic route of administration. (Item 76) The rAAV is about 1.0×10 based on supercoiled DNA or plasmid as the quantification standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 2.0×10 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5 × 10 13 vg / kg ~ approx. 2×1014 76. The use according to item 75, in a dose of 0.1 vg / kg. (Item 77) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg ~ approx. 2×10 14 76. The use according to item 75, in a dose of 0.1 vg / kg. (Item 78) The rAAV is about 5×10 based on supercoiled DNA or plasmid as the quantification standard. 13 vg / kg, approximately 1×10 14 vg / kg, or approximately 2 × 10 14 76. The use according to item 75, in a dose of 0.1 vg / kg. (Item 79) 1. Use of a recombinant adeno-associated virus (rAAV) AAVrh74.tMCK.hSCGA A for the preparation of a medicament for treating muscular dystrophy in a subject in need thereof, wherein the rAAV is capable of measuring approximately 1.85×10 13 vg / kg or 7.41 × 10 13 vg / kg and said medicament is formulated for systemic route of administration. (Item 80) The use according to any one of items 75 to 79, wherein the level of alpha-sarcoglycan gene expression in the cells of the subject is increased after administration of the pharmaceutical agent compared to the level of alpha-sarcoglycan gene expression before administration of the pharmaceutical agent, or the serum CK level in the subject is decreased after administration of the pharmaceutical agent compared to the serum CK level before administration of the pharmaceutical agent, or the number of alpha-sarcoglycan-positive fibers in the muscle tissue of the subject is increased after administration of rAAV compared to the number of alpha-sarcoglycan-positive fibers before administration of the pharmaceutical agent. (Item 81) 81. The use according to any one of items 75 to 80, wherein the systemic administration route is an intravenous route. (Item 82) 82. The use according to any one of items 75 to 81, wherein the medicament is formulated for administration by injection, infusion or implantation. (Item 83) 83. The use according to any one of items 75 to 82, wherein the medicament is formulated for administration by injection. (Item 84) 84. The use according to any one of items 75 to 83, wherein the medicament is formulated for administration by intravenous route via a peripheral limb vein. (Item 85) 85. The use of any one of items 75 to 84, wherein the rAAV comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1. (Item 86) 86. The use of item 85, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO:1. (Item 87) 87. The use of any one of items 75 to 86, wherein the rAAV comprises a nucleotide sequence encoding a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:2. (Item 88) 87. The use according to any one of items 75 to 86, wherein the rAAV comprises a nucleotide sequence encoding the polypeptide sequence shown in SEQ ID NO:2. (Item 89) The use of any one of items 75 to 86, wherein the rAAV comprises a scAAVrh74.tMCK.hSGCA construct nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:4. (Item 90) The use of item 89, wherein the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 91) 91. The use of any one of items 75 to 90, wherein the rAAV comprises a tMCK promoter. (Item 92) 92. The use of item 91, wherein the tMCK promoter comprises the nucleotide sequence shown in SEQ ID NO:3. (Item 93) 93. The use of any one of items 75 to 92, wherein the rAAV comprises the 5' inverted terminal repeat of SEQ ID NO:5. (Item 94) 94. The use of any one of items 75 to 93, wherein the rAAV comprises a 3' inverted terminal repeat of SEQ ID NO:6. (Item 95) 95. The use according to any one of items 73 to 94, wherein the rAAV comprises the polyA sequence of SEQ ID NO:7. (Item 96) 96. The use according to any one of items 73 to 95, wherein the rAAV is of the serotype AAVrh.74. (Item 97) 97. The use according to any one of items 73 to 96, wherein the muscular dystrophy is limb-girdle muscular dystrophy. (Item 98) 98. The use according to any one of items 73 to 97, wherein the muscular dystrophy is limb-girdle muscular dystrophy type 2D (LGMD2D). (Item 99) The subject is suffering from limb-girdle muscular dystrophy, the medicament is formulated for intravenous infusion, and the rAAV is administered at a concentration of about 5×10 based on the supercoiled DNA or plasmid as the quantitative standard. 13 vg / kg ~ approx. 2×10 14 99. The use of any one of items 73 to 98, wherein the rAAV is at a dose of 100 mg / kg and the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4. (Item 100) The use according to any one of items 73 to 99, wherein the level of alpha-sarcoglycan gene expression in the cells of the subject is increased after administration of the pharmaceutical agent compared to the level of alpha-sarcoglycan gene expression before administration of the pharmaceutical agent. (Item 101) 101. The use according to any one of items 73 to 100, wherein fibrosis is reduced in the subject after administration of the medicament compared to before administration of the medicament. (Item 102) The use according to any one of items 73 to 100, wherein fibrosis, centrosome formation, CK levels, and / or collagen deposition in the subject is reduced after administration of the medicament compared to the fibrosis before administration of the medicament. (Item 103) The use according to any one of items 72 to 102, wherein the specific force, fiber diameter size, and / or eccentric contraction in the muscle of the subject is increased after administration of the medicament compared to before administration of the medicament. (Item 104) The use according to item 100, wherein the alpha-sarcoglycan gene expression is detected by measuring alpha-sarcoglycan protein levels by Western blot and / or immunohistochemistry. (Item 105) Use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for expressing an alpha-sarcoglycan gene in a cell, wherein the scAAVrh74.tMCK.hSGCA construct comprises the nucleotide sequence of SEQ ID NO:4. (Item 106) The use according to item 105, wherein the expression of the alpha-sarcoglycan gene in the cells of the subject is detected by measuring alpha-sarcoglycan protein levels by Western blot in a muscle biopsy. (Item 107) The use according to item 105, wherein expression of the alpha-sarcoglycan gene in the cells is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry in muscle biopsies. (Item 108) Item 106. The use of item 105, wherein the expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA. (Item 109) Use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for reducing serum CK levels in a subject in need thereof, wherein the scAAVrh74.tMCK.hSGCA construct comprises the nucleotide sequence of SEQ ID NO:4. (Item 110) Use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for increasing alpha-sarcoglycan positive fibers in a subject's muscle tissue, wherein the scAAVrh74.tMCK.hSGCA construct comprises the nucleotide sequence of SEQ ID NO:4. (Item 111) Use of the scAAVrh74.tMCK.hSGCA construct for the preparation of a medicament for increasing expression of alpha-sarcoglycan in a subject in need thereof, wherein the scAAVrh74.tMCK.hSGCA construct comprises the nucleotide sequence of SEQ ID NO:4. (Item 112) 112. The method, composition or use according to any one of items 1 to 111, wherein the subject is a human subject aged between 4 and 15 years. (Item 113) 112. The method, composition or use according to any one of items 1 to 111, wherein the subject is a pediatric subject, an adolescent subject, or a young adult subject. (Item 114) 112. The method, composition or use of any one of items 1-111, wherein the subject is a human subject who is 4-15 years old, has a confirmed alpha-sarcoglycan (SGCA) mutation in both alleles, is negative for AAVrh74 antibodies, and / or has a 100 meter walk test of greater than 40% or normal. (Item 115) 112. The method, composition or use according to any one of items 1 to 111, wherein the subject is a middle-aged adult or an elderly subject. (Item 116) 112. The method, composition or use according to any one of items 1 to 111, wherein the subject is a human subject aged between 25 and 55 years. (Item 117) 112. The method, composition or use according to any one of items 1 to 111, wherein the subject is a human subject aged 50 years or older. (Item 118) 118. A method of generating the rAAV administered in the method, composition, or use of any one of claims 1 to 117, comprising transferring an AAV vector plasmid into a host cell, wherein the AAV vector plasmid comprises a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8. (Item 119) 19. The method of claim 118, wherein the AAV vector plasmid comprises the nucleotide sequence of SEQ ID NO:8. (Item 120) 120. The method of claim 118 or 119, wherein the vector plasmid comprises a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1, 4, or 8. (Item 121) 120. The method of claim 118 or 119, wherein the vector plasmid comprises the nucleotide sequence of SEQ ID NO: 1, 4, or 8. (Item 122) 122. The method of any one of items 118 to 121, further comprising transferring a packaging plasmid and / or a helper virus to the host cell. (Item 123) 123. The method of any one of items 118 to 122, wherein the packaging cells contain a stably integrated AAVcap gene. (Item 124) 124. The method of any one of items 118 to 123, wherein the packaging cells contain a stably integrated AAVrep gene. (Item 125) A host cell comprising an AAV vector plasmid comprising a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1, 4, or 8. (Item 126) 126. The host cell of claim 125, wherein the AAV vector plasmid comprises the nucleotide sequence of SEQ ID NO: 1, 4, or 8. [Brief description of the drawings]
[0054] [Figure 1] The scAAVrh74.tMCK.hSGCA gene cassette is shown. [Figure 2-1] Transgene expression in a dose-escalation study following systemic treatment with scAAVrh74.tMCK.hSGCA is shown. (A) Alpha-sarcoglycan immunofluorescence staining of multiple muscles from mice treated systemically (intravenously) with 1x1012vg, 3x1012vg, and 6x1012vg (or 5x1013vg / kg, 1x1014vg / kg, and 2x1014vg / kg, respectively, based on a 20 g mouse) (n=6 per group). Myofibers expressing alpha-sarcoglycan at 12 weeks post-treatment ranged from 70%-93% compared to untreated controls. (B) Western blot of muscles from treated sgca- / - mice confirms hSGCA protein expression. Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; TRI, triceps; GLUT, gluteus; PSO, psoas; DIA, diaphragm; HRT, heart; WT, wild type. [Figure 2-2]Transgene expression in a dose-escalation study following systemic treatment with scAAVrh74.tMCK.hSGCA is shown. (A) Alpha-sarcoglycan immunofluorescence staining of multiple muscles from mice treated systemically (intravenously) with 1x1012vg, 3x1012vg, and 6x1012vg (or 5x1013vg / kg, 1x1014vg / kg, and 2x1014vg / kg, respectively, based on a 20 g mouse) (n=6 per group). Myofibers expressing alpha-sarcoglycan at 12 weeks post-treatment ranged from 70%-93% compared to untreated controls. (B) Western blot of muscles from treated sgca- / - mice confirms hSGCA protein expression. Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; TRI, triceps; GLUT, gluteus; PSO, psoas; DIA, diaphragm; HRT, heart; WT, wild type. [Figure 3-1] Improved muscle morphology by scAAVrh74.tMCK.hSGCA in sgca- / - mice, independent of dose. (A) Hematoxylin and eosin images of various muscles from sgca- / - mice treated with 1x1012vg, 3x1012vg, and 6x1012vg (or 5x1013vg / kg, 1x1014vg / kg, and 2x1014vg / kg, respectively, based on a 20 g mouse). Representative 20x images show a dramatic reduction in central nuclei and an overall normalization of fiber size, independent of treatment dose. (B) Quantification confirming normalization of myofiber diameters of various muscles in treatment groups compared to vehicle-treated mice and wild-type controls (n=6 per group). (C) Quantification of centrally located nuclei in muscles of treated mice compared to untreated and wild-type controls (n=6 per group). Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; GLUT, gluteus; PSO, psoas; TRI, triceps; DIA, diaphragm; WT, wild-type. [Figure 3-2]Improved muscle morphology by scAAVrh74.tMCK.hSGCA in sgca- / - mice, independent of dose. (A) Hematoxylin and eosin images of various muscles from sgca- / - mice treated with 1x1012vg, 3x1012vg, and 6x1012vg (or 5x1013vg / kg, 1x1014vg / kg, and 2x1014vg / kg, respectively, based on a 20 g mouse). Representative 20x images show a dramatic reduction in central nuclei and an overall normalization of fiber size, independent of treatment dose. (B) Quantification confirming normalization of myofiber diameters of various muscles in treatment groups compared to vehicle-treated mice and wild-type controls (n=6 per group). (C) Quantification of centrally located nuclei in muscles of treated mice compared to untreated and wild-type controls (n=6 per group). Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; GLUT, gluteus; PSO, psoas; TRI, triceps; DIA, diaphragm; WT, wild-type. [Figure 4] Figure 1 shows reduced fibrosis in sgca- / - mice treated with scAAVrh74.tMCK.hSGCA. (A) Picrosirius red staining shows reduced fibrosis in mice treated with scAAVrh74.tMCK.hSGCA, as indicated by reduced collagen deposition, compared to vehicle-treated sgca- / - mice, in various muscles of representative 20x images shown. (B) Quantification of collagen levels in various muscles confirms reduced collagen levels in all three treatment groups compared to untreated mice and wild-type controls (n=6 per group). Abbreviations: PSO, psoas; DIA, diaphragm; TRI, triceps; GLUT, gluteus. [Diagram 5]Skeletal muscle functional benefits following treatment with scAAVrh74.tMCK.hSGCA. (A) After 3 months of treatment, tibialis anterior (TA) muscles were harvested (both left and right) to measure specific force and resistance to contraction-induced damage (normalized to TA weight). Quantification of specific force and eccentric contraction was increased in all treatment groups (with minimal differences between doses) compared to untreated controls (n=6 per group). (B) Diaphragm muscle strips were harvested to measure specific force. After 12 weeks of treatment, force was significantly increased in treated mice compared to untreated sgca- / - mice. (C) After 12 weeks of treatment, open field analysis of treated mice showed improvements in gait and vertical activity compared to untreated sgca- / - controls (n=6 per group). (D) Serum creatine kinase levels were decreased in all treatment groups compared to untreated sgca- / - controls. Data were analyzed by one-way ANOVA followed by Tukey's post-hoc analysis for multiple comparisons. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 compared to vehicle-treated sgca- / - mice unless otherwise stated. Abbreviations: TA, tibialis anterior; DIA, diaphragm; WT, wild type. [Figure 6] Blood chemistry shows no evidence of toxicity following treatment with scAAVrh74.tMCK.hSGCA. Toxicity of liver enzymes (ALT, AST, and ALP / K) and blood glucose (GLU) levels were analyzed (n=6 per group). All chemical values of treated mice were within normal / healthy limits for the mice, as indicated by the dotted lines. [Figure 7A] Figure 1 shows biodistribution analysis of systemic scAAVrh74.tMCK.hSGCA delivery-distribution histograms of mean vg copies of transcript per microgram of DNA added to quantitative polymerase chain reaction in various tissues from sgca- / - mice following intravenous delivery of 3 x 1012 vg and 6 x 1012 vg (or 1 x 1014 vg / kg and 2 x 1014 vg / kg, respectively, based on a 20 g mouse) of scAAVrh74.tMCK. [Figure 7B]Western blots of alpha-sarcoglycan protein expression in livers of WT and sgca− / − mice treated with either vehicle (sgca− / − LR (lactated ringer)) or scAArh74.tMCK.hSGCA at 1.0×1012 vg (left western blot) or 6×1012 vg (right western blot). Each lane represents an independent mouse (M1: mouse 1, M2: mouse 2, M3: mouse 3). The bottom panel represents vinculin, which was used as a loading control. Abbreviations: DIA, diaphragm; TA, tibialis anterior; TRI, triceps brachii. [Figure 8] Expression of scAAVrh74.tMCK.hSGCA in skeletal muscle of 12-month-old sgca mice by immunofluorescence (Figure 8A) and Western blot (Figure 8B). The graph in Figure 8C provides the percentage of positive muscle fibers in sgca mice for scAAVrh74.tMCK.hSGCA. Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; GLUT, gluteus; TRI, triceps; PSOAS, psoas, diaphragm; WT, wild type; LRS, lactated Ringer's solution. [Figure 9-1] Histological results of administration of scAAVrh74.tMCK.hSGCA in 12-month-old SGCA- / - mice. Figure 9a shows improved muscle pathology. Figure 9b shows reduced central nucleation and increased average fiber size in gastrocnemius (GAS) and triceps brachii (TRI). Figure 9c shows reduced levels of fibrosis compared to untreated controls. Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; GLUT, gluteus; PSO, psoas; TRI, triceps; diaphragm; WT, wild type. [Figure 9-2]Histological results of administration of scAAVrh74.tMCK.hSGCA in 12-month-old SGCA- / - mice. Figure 9a shows improved muscle pathology. Figure 9b shows reduced central nucleation and increased average fiber size in gastrocnemius (GAS) and triceps brachii (TRI). Figure 9c shows reduced levels of fibrosis compared to untreated controls. Abbreviations: TA, tibialis anterior; GAS, gastrocnemius; QD, quadriceps; GLUT, gluteus; PSO, psoas; TRI, triceps; diaphragm; WT, wild type. [Figure 10] 1 shows improved functionality in aged mice following administration of scAAVrh74.tMCK.hSGCA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0055] The present disclosure is based on the discovery that administration of rAAV containing a polynucleotide expressing alpha-sarcoglycan results in the reduction or complete recovery of muscle fibrosis in an animal model of limb-girdle muscular dystrophy. As demonstrated in the Examples herein, administration of the rAAV described herein resulted in the reversal of dystrophic features, including reduced CK levels, increased muscle strength, improved gait and vertical activity, and other motor functions.
[0056] The practice of the present invention employs, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology, and recombinant DNA technology, within the skill of one of ordinary skill in the art. Such techniques are fully explained in the literature. See, for example, Sambrook et al. Molecular Cloning: A Laboratory Manual (Current Edition); DNA Cloning: A Practical Approach, Vol. I & II (D. Glover, ed.); Oligonucleotides and Their Recombinants (Oligonucleotides and Their Recombinants), Vol. 1, Vol. 2, Vol. 3, Vol. 4, Vol. 5, Vol. 6, Vol. 7, Vol. 8, Vol. 9, Vol. 10, Vol. 11, Vol. 12, Vol. 13, Vol. 14, Vol. 15, Vol. 16, Vol. 17, Vol. 18, Vol. 19, Vol. 20, Vol. 21, Vol. 22, Vol. 23, Vol. 24, Vol. 25, Vol. 26, Vol. 27, Vol. 28, Vol. 30, Vol. 31, Vol. 32, Vol. 33, Vol. 34, Vol. 35, Vol. 36, Vol. 37, Vol. 38, Vol. 39, Vol. 40, Vol. 41, Vol. 42, Vol. 43, Vol. 44, Vol. 45, Vol. 46, Vol. 47, Vol. 48, Vol. 50, Vol. 51, Vol. 52, Vol. 53, Vol. 54, Vol. 55, Vol. 56, Vol. 57, Vol. 58, Vol. 59, Vol. 60, Vol. 61, Vol. 62, Vol. 63, Vol. 64, Vol. 65, Vol. 66, Vol. 67, Vol. 6 Synthesis (N. Gait, ed., Current Edition), Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., Current Edition), Transcription and Translation (B. Hames & S. Higgins, eds., Current Edition), CRC Handbook of Parvoviruses, vol. I&II (P. Tijssen, ed.), Fundamental See Virology, 2nd Edition, vol. I & II (BN Fields and DM Knipe, eds.), Freshney Culture of Animal Cells, A Manual of Basic Technique (Wiley-Liss, Third Edition), and Ausubel et al. (1991) Current Protocols in Molecular Biology (Wiley Interscience, NY).
[0057] All publications, patents, and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
[0058] definition The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "cell" includes a plurality of such cells, a reference to a "culture" includes a reference to one or more cultures and equivalents thereof known to those skilled in the art, and so forth. A reference to a "recombinant AAV" includes a mixture of two or more rAAV virions, and so forth. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.
[0059] Use of the term "or" in the claims is used to mean "and / or," unless expressly indicated to refer only to alternatives or where the alternatives are mutually exclusive, however, the present disclosure supports a definition that refers only to alternatives and "and / or."
[0060] Throughout this application, the term "about" is used to indicate that a value includes statistical experimental error (the standard deviation of error) for the device or method being employed to determine the value.
[0061] The term "vector" or "expression vector" refers to any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc., that can replicate and transfer genetic sequences between cells when associated with the appropriate control elements. In one embodiment, the vector is a viral vector. Expression vectors can contain various control sequences, structural genes (e.g., genes of interest), and nucleic acid sequences that also perform other functions.
[0062] As used herein, the term "AAV" is a general abbreviation for adeno-associated virus. Adeno-associated virus is a single-stranded DNA parvovirus that grows only in cells where certain functions are provided by a co-infecting helper virus. Currently, there are 13 serotypes of AAV that have been characterized. General information and reviews of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). However, it is well known that various serotypes are very closely related, both structurally and functionally, even at the genetic level, so it is fully expected that these same principles will be applicable to additional AAV serotypes. (See, e.g., Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J.R. Puttson, ed., and Rose, Comprehensive Virology 3:1-61 (1974).) For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes, and they all have three related capsid proteins, such as those expressed in AAV2. The degree of relatedness is further suggested by extensive cross-hybridization between serotypes along the length of the genome, and heteroduplex analysis, which reveals the presence of similar self-annealing segments at the ends corresponding to "inverted terminal repeats" (ITRs). Similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.
[0063] The term "AAV vector" refers to one or more polynucleotides of interest (or transgenes) flanked by AAV terminal repeats (ITRs). Such AAV vectors can replicate and be packaged into infectious viral particles when present in a host cell transfected with a vector encoding and expressing rep and cap gene products. In one embodiment, the AAV vector is a vector derived from an adeno-associated virus serotype, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV rh10, and AAV rh74. AAV vectors can be deleted in whole or in part of one or more of the AAV wild-type genes, preferably the rep and / or cap genes, but retain functional flanking ITR sequences. Functional ITR sequence is necessary for AAV virion rescue, replication and packaging.Therefore, AAV vector is defined herein to include at least those sequences that are required in cis for viral replication and packaging (e.g., functional ITR).ITR does not need to be wild-type nucleotide sequence, and can be modified, for example, by nucleotide insertion, deletion or substitution, as long as the sequence provides functional rescue, replication and packaging.
[0064] The term "AAV helper functions" refers to AAV-derived coding sequences that can be expressed to provide AAV gene products that then function in trans for productive AAV replication. Thus, AAV helper functions include the major AAV open reading frames (ORFs), rep, and cap. The Rep expression product has been shown to possess many functions, including, among others, recognition, binding, and nicking of the AAV origin of DNA replication, DNA helicase activity, and regulation of transcription from AAV (or other heterologous) promoters. The Cap expression product supplies the necessary packaging functions. AAV helper functions are used herein to complement AAV functions in trans that are missing from AAV vectors.
[0065] By "recombinant virus" is meant a virus that has been genetically altered, for example, by the addition or insertion of a heterologous nucleic acid sequence into the viral particle.
[0066] "AAV virion" or "AAV virus particle" or "AAV vector particle" refers to a virus particle consisting of at least one AAV capsid protein and a polynucleotide AAV vector enclosed in the capsid. In one embodiment, the AAV virion comprises a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene delivered to a mammalian cell). In one embodiment, the production of the AAV virus particle comprises the production of an AAV vector, e.g., the vector is contained within the AAV vector particle. When a particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene delivered to a mammalian cell), it is typically referred to as a "rAAV vector" or simply an "rAAV particle". Thus, the production of the AAV vector particle necessarily comprises the production of a rAAV, and the rAAV genome is contained within the rAAV vector particle.
[0067] For example, a wild-type (wt) AAV virus particle comprises a linear, single-stranded AAV nucleic acid genome associated with an AAV capsid protein coat. AAV virions can be either single-stranded (ss) AAV or self-complementary (SC) AAV. In one embodiment, single-stranded AAV nucleic acid molecules of complementary sense, e.g., either the "sense" or "antisense" strand, can be packaged into an AAV virion, and both strands are equally infectious.
[0068] The term "recombinant AAV" or "rAAV" is defined herein as an infectious, replication-defective virus consisting of an AAV protein shell that encapsulates a heterologous nucleotide sequence of interest flanked by AAV ITRs. In one embodiment, rAAV is produced in a suitable host cell, which has an AAV vector, AAV helper functions, and accessory functions introduced therein. In this way, the host cell can encode the AAV polypeptides required to package the AAV vector (containing the recombinant nucleotide sequence of interest) into an infectious recombinant virion particle for subsequent gene delivery.
[0069] The term "transfection" refers to the uptake of foreign DNA by a cell, and a cell is "transfected" when exogenous DNA is introduced into the cell membrane. Many transfection techniques are generally known in the art. See, for example, Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Using such techniques, one or more foreign DNA moieties, such as nucleotide integration vectors and other nucleic acid molecules, can be introduced into a suitable host cell.
[0070] The term "transduction" refers to the delivery of a DNA molecule to a recipient cell either in vivo or in vitro via a replication-defective viral vector, for example, via a recombinant AAV virion.
[0071] The term "host cell" refers to, for example, microorganisms, yeast cells, insect cells, and mammalian cells that can be or have been used as recipients of AAV helper constructs, AAV vector plasmids, accessory function vectors, or other transfer DNA. The term includes the progeny of the original cell that was transfected. Thus, as used herein, "host cell" generally refers to a cell that has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parent cell may not necessarily be completely identical in morphology or genome or total DNA complement due to natural, accidental, or deliberate mutations.
[0072] The term "heterologous" when referring to nucleic acid sequences, such as coding sequences and control sequences, refers to sequences that are not normally linked together and / or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct or vector is a segment of nucleic acid attached within or to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a nucleic acid construct may include a coding sequence flanked by sequences that are not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct in which the coding sequence itself is not found in nature (e.g., a synthetic sequence with codons different from the native gene). Similarly, a cell transformed with a construct that is not normally present in the cell would be considered heterologous for the purposes of the present invention. As used herein, allelic variations or naturally occurring mutational events do not give rise to heterologous DNA.
[0073] A "coding sequence" or a sequence that "encodes" a particular protein is a nucleic acid sequence that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. Coding sequences include, but are not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.
[0074] "Nucleic acid" sequence refers to a DNA or RNA sequence. Nucleic acids include 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil , 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid, oxybutoxocine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, -uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.
[0075] The term DNA "control sequences" collectively refers to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription, and translation of a coding sequence in a recipient cell. Not all of these control sequences need always be present so long as the selected coding sequence is capable of being replicated, transcribed, and translated in an appropriate host cell.
[0076] The term "promoter" is used herein in its ordinary sense to refer to a nucleotide region that contains DNA regulatory sequences derived from a gene capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence. Transcriptional promoters can include "inducible promoters" (expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), "repressible promoters" (expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), and "constitutive promoters." In one embodiment, the promoter is a muscle-specific promoter, including, but not limited to, human skeletal actin gene element, cardiac actin gene element, desmin promoter, skeletal alpha actin (ASKA) promoter, troponin I (TNNI2) promoter, muscle cell specific enhancer binding factor mef binding element, muscle creatine kinase (MCK) promoter, truncated MCK (tMCK) promoter, myosin heavy chain (MHC) promoter, hybrid a-myosin heavy chain enhancer / MCK enhancer promoter (MHCK7) promoter, C5-12 promoter, mouse creatine kinase enhancer element, skeletal fast troponin c gene element, slow cardiac troponin c gene element, slow troponin i gene element, hypoxia-inducible nuclear factor (HIF) response element (HRE), steroid-inducible element, and glucocorticoid response element (gre). In another embodiment, the promoter is an MCK promoter, a tMCK promoter, or an MHCK7 promoter.
[0077] The term "operably linked" refers to an arrangement of elements such that the components so described are configured to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of affecting the expression of the coding sequence. Control sequences need not be contiguous with the coding sequence, so long as they function to direct its expression. Thus, for example, intervening untranslated but transcribed sequences can be present between the promoter sequence and the coding sequence, and the promoter sequence can still be considered "operably linked" to the coding sequence.
[0078] A promoter "directs the transcription" of a coding sequence in a cell when RNA polymerase binds to the promoter sequence and transcribes the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
[0079] "Expression cassette" or "expression construct" refers to an assembly capable of directing the expression of a sequence(s) or gene(s) of interest. An expression cassette, as described above, includes control elements such as a promoter operably linked (to direct transcription) to a sequence(s) or gene(s) of interest, and often also includes a polyadenylation sequence. Within certain embodiments of the invention, the expression cassettes described herein may be included within a plasmid construct. In addition to the components of the expression cassette, the plasmid construct may also include one or more selectable markers, a signal that allows the plasmid construct to exist as single-stranded DNA, at least one multiple cloning site, and a "mammalian" origin of replication (e.g., SV40 or adenovirus origin of replication).
[0080] "Isolated" when referring to a nucleotide sequence means that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other nucleotide sequences, chromatin material, etc. Thus, an "isolated nucleic acid molecule encoding a particular polypeptide" refers to a nucleic acid molecule that is substantially free of other nucleic acid molecules that do not encode the polypeptide of interest; however, the molecule may contain some additional bases or moieties that do not adversely affect the basic properties of the composition.
[0081] For purposes of describing the relative position of a nucleotide sequence in a particular nucleic acid molecule throughout this application, such as when a particular nucleotide sequence is described as being located "upstream," "downstream," "3," or "5" relative to another sequence, it is to be understood that this is the location of the sequence on the "sense" or "coding" strand of the DNA molecule as that is conventionally referred to in the art.
[0082] The terms "sequence identity," "percent sequence identity," or "percent identical" in the context of nucleic acid or amino acid sequences refer to residues in two sequences that are the same when aligned for maximum correspondence. The length of sequence identity comparison can be the full length of a genome, the full length of a gene coding sequence, or a fragment of at least about 500-5000 nucleotides is desirable. However, identity between smaller fragments, such as at least about 9 nucleotides, usually at least about 20-24 nucleotides, at least about 28-32 nucleotides, at least about 36 nucleotides or more, may also be desirable. Percent sequence identity can be determined by techniques known in the art. For example, homology can be determined by directly comparing the sequence information between two polypeptide molecules by aligning the sequence information and using readily available computer programs such as ALIGN, ClustalW2, and BLAST. In one embodiment, when BLAST is used as the alignment tool, the following default parameters are used: genetic code=standard; filter=none; strand=both; cutoff=60; prediction=10; matrix=BLOSUM62; explanation=50 sequences; sort=high score; database=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translation+Swiss Protein+Spupdate+PIR.
[0083] The term "subject" refers to any member of the animal kingdom, including, but not limited to, humans and non-human primates such as chimpanzees and other apes and monkey species, farm animals such as cows, sheep, pigs, goats, and horses, domestic mammals such as dogs and cats, laboratory animals including rodents such as mice, rats, and guinea pigs, and the like. In some embodiments, the subject is a human in the age range of birth to 2 years, 1 to 10 years, or 4 to 15 years, or 10 to 19 years, or 20 to 40 years, or 15 to 29 years, or 25 to 55 years, or 40 to 60 years, or 50 years or older, or 60 years or older, or 65 years or older, or 70 years or older. For example, the subject is a human child (2 to 12 years), a human adolescent (10 to 19 years). In some embodiments, the subject is an adult (18 years or older). In particular, the subject may be a young adult (15-29 years old), a middle-aged adult (25-55 years old), or an older adult (50 years or older), or an elderly human subject (65 years or older), or a geriatric human subject (70 years or older).
[0084] "Therapeutic effect" refers to any therapeutic benefit provided by the treatment described herein. For example, such an effect may be the sustained expression of a protein or enzyme that is defective or deficient in the muscular dystrophy of interest in the appropriate target tissue. Furthermore, the therapeutic effect may be any reduction or elimination of one or more clinical or subclinical signs of the disease or disorder of interest. For example, a reduction in CK levels, a reduction in fibrosis, an increase in resistance to contraction-induced damage in the tibialis anterior muscle, and / or an increase in intramuscular specific force, and an improvement in motor function provide a therapeutic benefit to the treated subject with LGMD-2D.
[0085] In another aspect, the recombinant AAV vector described herein comprises a polynucleotide sequence encoding an alpha-sarcoglycan that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:2, or the protein retains alpha-sarcoglycan activity. In another embodiment, the alpha-sarcoglycan comprises the polypeptide sequence set forth in SEQ ID NO:2.
[0086] In another aspect, described herein is a recombinant AAV vector comprising a polynucleotide sequence encoding a functional alpha-sarcoglycan comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1, or a complement thereof. In another embodiment, the rAAV comprises a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 4. In another embodiment, the rAAV comprises the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4.
[0087] The term "stringent" is used to refer to conditions that are generally understood in the art as stringent. Hybridization stringency is determined primarily by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015M sodium chloride, 0.0015M sodium citrate at 65-68°C or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY1989). More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agents) can also be used, but the rate of hybridization will be affected. Where deoxyoligonucleotide hybridization is concerned, examples of additional stringent hybridization conditions include washing in 6×SSC, 0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for 17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-base oligos).
[0088] When ranges are used herein for physical properties such as molecular weight, concentration, or dosage, all combinations and subcombinations of the ranges and specific embodiments therein are intended to be included. The term "about" when referring to a numerical value or numerical range means that the referenced numerical value or numerical range is an approximation within experimental variation (or within statistical experimental error), and thus the numerical value or numerical range may vary, for example, between 1% and 15% of the stated numerical value or numerical range.
[0089] Other agents can be included in the hybridization and washing buffers to reduce nonspecific and / or background hybridization. Examples include 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecyl sulfate, NaDodSO4, (SDS), Ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, but other suitable agents can be used. The concentration and type of these additives can be varied without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually performed at pH 6.8-7.4, but under typical ionic strength conditions, the rate of hybridization is largely independent of pH. See Anderson et al., Nucleic Acid Hybridisation: A Practical Approach, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one of skill in the art to take these variables into account, allowing DNAs of different sequence similarity to form hybrids.
[0090] Limb-girdle muscular dystrophy type 2D (LGMD2D) is a progressive muscular dystrophy associated with muscle weakness, respiratory abnormalities, and rarely, cardiomyopathy. LGMD2D is caused by mutations in the alpha-sarcoglycan gene, resulting in loss of protein and concomitant loss of sarcoglycan and dystrophin-associated glycoprotein complexes. Sgca-null (sgca - / - ) mice recapitulate the clinical phenotype of LGMD2D patients, including dystrophic features such as muscle necrosis and fibrosis, elevated serum creatine kinase (CK), and reduced absolute muscle strength and locomotor activity. - / -Mice provide a relevant model for testing the safety and efficacy of gene replacement. Accordingly, the present disclosure provides a self-complementary AAVrh74 vector containing a codon-optimized full-length human SGCA (hSGCA) transgene driven by a muscle-specific promoter, truncated muscle creatine kinase (tMCK). - / - Efficacy and safety of scAAVrh74.tMCK.hSGCA in mice compared to vehicle-treated and wild-type mice at 1 × 10 12、3 ×10 12 , and 6 × 10 12 A dose-escalation design was used to evaluate a single systemic injection of VG. - / - In mice, treatment with scAAVrh74.tMCK.hSGCA resulted in robust protein expression of α-SG in the sarcolemma of skeletal muscle at all doses tested. Furthermore, scAAVrh74.tMCK.hSGCA downregulated sgca expression in the sarcolemma of skeletal muscle, as shown by reduced fibrosis and central nucleation, as well as normalization of myofiber size. - / - It was effective in improving the histopathology of the limb and diaphragm muscles of mice. These molecular changes were accompanied by a significant increase in specific force generation in the diaphragm and tibialis anterior muscles, protection against eccentric force loss, and a reduction in serum CK. Locomotor activity was significantly higher in vehicle-treated sgca mice than in control mice. - / - The overall survival of mice treated with scAAVrh74.tMCK.hSGCA was improved at all doses in mice treated with vector compared to mice treated with scAAVrh74.tMCK.hSGCA. Finally, a lack of vector-associated toxicity was detected by serum chemistry panels and gross necropsy. Collectively, this study provides support for systemic delivery of scAAVrh74.tMCK.hSGCA in a clinical setting for the treatment of LGMD2D.
[0091] In another embodiment, the recombinant AAV vector described herein can be operably linked to a muscle-specific regulatory element. For example, the muscle-specific promoter includes one or more of human skeletal actin gene element, cardiac actin gene element, desmin promoter, skeletal alpha actin (ASKA) promoter, troponin I (TNNI2) promoter, muscle cell specific enhancer binding factor mef binding element, muscle creatine kinase (MCK) promoter, truncated MCK (tMCK) promoter, myosin heavy chain (MHC) promoter, hybrid a-myosin heavy chain enhancer / MCK enhancer promoter (MHCK7) promoter, C5-12 promoter, mouse creatine kinase enhancer element, fast skeletal troponin c gene element, slow cardiac troponin c gene element, slow troponin i gene element, hypoxia-inducible nuclear factor (HIF) response element (HRE), steroid-inducible element, and glucocorticoid response element (gre).
[0092] In one embodiment, the muscle-specific promoter is the tMCK promoter comprising the sequence of SEQ ID NO: 3. An exemplary rAAV described herein is AAVrh74.tMCK.hSCGA, which comprises the nucleotide sequence of SEQ ID NO: 4. In some embodiments, the polynucleotide sequence encoding AAVrh74.tMCK.hSCGA comprises a sequence that is at least 65%, about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to the nucleotide sequence set forth in SEQ ID NO:4, or to a nucleotide sequence that is at least 65%, about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to SEQ ID NO:1.
[0093] In another embodiment, the polynucleotide encoding AAVrh74.tMCK.hSCGA comprises a nucleotide sequence that encodes a polypeptide sequence that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to the nucleotide sequence set forth in SEQ ID NO: 1. In some embodiments, the polynucleotide sequence encodes a protein that retains alpha-sarcoglycan activity.
[0094] In one embodiment, the rAAV comprises the 5' inverted terminal repeat of SEQ ID NO: 5. In another embodiment, the rAAV comprises the 3' inverted terminal repeat of SEQ ID NO: 6. In some embodiments, the rAAV comprises the polyA sequence of SEQ ID NO: 7.
[0095] The AAV can be any serotype, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-10, AAV-11, AAV-12, AAV-13, AAV rh.10, AAV rh.74, or mutants and derivatives thereof. In one embodiment, the rAAV is an rAAV of serotype AAVrh.74. The production of pseudotyped rAAV is disclosed, for example, in WO2001 / 083692, which is incorporated herein by reference in its entirety. Other types of rAAV mutants, for example, rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909(2014).
[0096] Compositions comprising any of the rAAV vectors described herein are also contemplated.
[0097] Provided is a method of treating muscular dystrophy in a subject in need thereof, comprising administering a recombinant adeno-associated virus (rAAV) scAAVrh74.tMCK.hSGCA, wherein the rAAV is administered in a concentration of about 1.0×10 12vg / kg ~ approx. 5.0×10 15 For example, in any of the methods provided, the dose of rAAV administered is about 1.0×10 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 5×10 13 vg / kg ~ approx. 2×10 14 vg / kg, or approximately 2.0 × 10 13 vg / kg ~ approx. 3.0×10 14 In another embodiment, the dose is about 5.0×10 13 vg / kg, 1.0×10 14 vg / kg, or 2.0 × 10 14 In one embodiment, the rAAV is administered by a systemic route, including an intravenous route. In another embodiment, the rAAV is administered at a dose of about 5.0×10 13 vg / kg, 1.0×10 14 vg / kg, or 2.0 × 10 14 vg / kg intravenously. In one embodiment, the muscular dystrophy is limb-girdle muscular dystrophy.
[0098] In addition, the dose of rAAV administered is approximately 1.5×10 13 vg~approx.3.5×10 16 vg, or approximately 3 × 10 13 vg~approx. 1.0×10 16 vg, or approximately 1.5 × 10 13 vg~approx. 2×10 15 vg, or approximately 1.5 × 10 13 vg~approx. 1×10 14In one embodiment, the muscular dystrophy is limb-girdle muscular dystrophy type 2D. The doses in this disclosure are expressed in either vg or vg / kg and are based on quantitative PCR (qPCR) titration qualification. qPCR-based titration methods are known in the art.
[0099] Additionally, provided is a method of treating muscular dystrophy in a subject in need thereof, comprising administering a recombinant adeno-associated virus (rAAV) scAAVrh74.tMCK.hSGCA, wherein the rAAV is administered at a concentration of about 1.0×10 12 vg / kg ~ approx. 2.0×10 15vg / kg, and the level of alpha-sarcoglycan gene expression in the subject's cells is increased after administration of rAAV compared to the level of alpha-sarcoglycan gene expression before administration of rAAV, the serum CK level in the subject is decreased after administration of rAAV compared to the serum CK level before administration of rAAV, and / or locomotor activity and specific force production are increased, fibrosis is reduced, resistance to contraction-induced damage of the tibialis anterior muscle is increased, and / or the number of alpha-sarcoglycan positive fibers in the subject's muscle tissue is increased after administration of rAAV compared to the number of alpha-sarcoglycan positive fibers before administration of rAAV, the fiber diameter size in the subject's muscle tissue is increased after administration of rAAV compared to the number of fiber diameters before administration of rAAV, or central nucleation in the subject's muscle tissue is decreased after administration of rAAV compared to central nucleation before administration of rAAV. Muscle tissue includes, but is not limited to, triceps, tibialis anterior, soleus, gastrocnemius, biceps, trapezius, gluteus, psoas, deltoid, quadriceps, and diaphragm. In one embodiment, muscle tissue includes tibialis anterior, gastrocnemius, gluteus, psoas, and triceps. Alpha-sarcoglycan expression is determined by methods known to those skilled in the art. In one embodiment, expression is determined by Western blot, immunochemistry in muscle biopsy, and / or by detecting the number of vector genomes per microgram of genomic DNA.
[0100] In some embodiments, the disclosure includes a method of treating muscular dystrophy in a subject in need thereof, comprising administering a recombinant adeno-associated virus (rAAV) scAAVrh74.tMCK.hSGCA, wherein motor function is significantly improved in the subject compared to the subject's motor function prior to administration of the rAAV.
[0101] Provided is a method of increasing expression of alpha-sarcoglycan in a subject in need thereof comprising administering to the patient the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0102] In any of the methods, uses, and compositions for treating muscular dystrophy provided, the subject is 4-15 years old, has a confirmed alpha-sarcoglycan (SGCA) mutation in both alleles, is negative for AAVrh74 antibodies, and / or has a 100 meter walk test of greater than 40% or normal. In any of the methods, uses, and compositions for treating muscular dystrophy provided, the subject is a pediatric subject. In some embodiments, the subject is a pediatric subject, for example, a subject in the age range of 1-21 years old. In some embodiments, the subject is 1-10 years old, or 2-12 years old, 4-15 years old, or 10-19 years old. In one embodiment, the subject is an adolescent subject, for example, a subject in the age range of 12-21 years old. Additionally, the subject is a young adult subject, such as a subject in the age range of 15-29 years old or 18-39 years old, in one embodiment. In some embodiments, the subject is a middle-aged adult or an elderly subject, such that a middle-aged adult may range from 25 to 55 years old, an older adult subject may range over 50 years old, and an elderly subject may range over 65 years old. In some embodiments, the rAAV is administered by injection, infusion, or implantation. For example, the rAAV is administered by infusion over approximately 1 to 2 hours. Additionally, the rAAV is administered by an intravenous route via a peripheral limb vein.
[0103] In a method of treating muscular dystrophy in a subject in need thereof, comprising administering recombinant adeno-associated virus (rAAV) scAAVrh74.tMCK.hSGCA, the rAAV is administered at a concentration of about 1.0×10 12 vg / kg ~ approx. 5.0×10 14vg / kg, and the rAAV comprises a nucleotide sequence that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. In another embodiment, the rAAV comprises a nucleotide sequence as set forth in SEQ ID NO: 1. In one embodiment, the rAAV encodes a protein comprising a polypeptide sequence that is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:2. In another embodiment, the rAAV comprises a nucleotide sequence encoding a protein comprising the polypeptide sequence shown in SEQ ID NO:2. Additionally, any of the disclosed rAAVs further comprises a promoter, such as the tMCK promoter sequence of SEQ ID NO:3. In some embodiments, the rAAV is of serotype AAVrh.74. Additionally, the rAAV comprises the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:3. In one embodiment, the rAAV comprises the 5' inverted terminal repeat sequence of SEQ ID NO:5. In another embodiment, the rAAV comprises the 3' inverted terminal repeat sequence of SEQ ID NO:6. In another embodiment, the rAAV comprises the polyA sequence of SEQ ID NO:7.
[0104] AAV dosage can be determined by multiple methods, including but not limited to LISA, assessment of reverse transcriptase activity, FACS, transduction assays, Northern blotting (e.g., semi-quantitative Northern), dot blot analysis, or PCR (e.g., qPCR). It is well known that the dosage of AAV can be determined by measuring the AAV vector genome with quantitative real-time PCR (qPCR). Such qPCR methods overcome the inconsistent or arbitrary results from traditional transduction assays. In one embodiment of PCR dosage determination, plasmid DNA is used as a calibration standard. The morphology of the plasmid can affect the dosage results by qPCR methods. In one embodiment, circular or supercoiled DNA or plasmid is used as a quantification standard. In another embodiment, linearized DNA or plasmid is used as a quantification standard.
[0105] The term "supercoiled DNA" or "supercoiled plasmid" refers to DNA or a plasmid that does not contain free ends. The term "linearized DNA" or "linearized plasmid" refers to DNA or a plasmid that contains a free 5' end and a free 3' end that are not linked to each other. In one embodiment, the linearized DNA or plasmid is obtained by restriction digestion of a circular DNA (e.g., plasmid DNA) or by restriction digestion of dbDNA. In another embodiment, the restriction digestion is performed using an enzyme that generates at least one blunt end.
[0106] In an exemplary embodiment, a method for treating muscular dystrophy in a subject in need thereof includes administering recombinant adeno-associated virus (rAAV) scAAVrh74.tMCK7.hSGCA, wherein the rAAV is administered at a dose of about 1.0×10 12 vg / kg ~ approx. 5.0×10 14 In one embodiment, the rAAV is administered at a dose of about 5.0×10 vg / kg, and the human subject is afflicted with limb-girdle muscular dystrophy. In one embodiment, the rAAV is administered at a dose of about 5.0×10 13 vg / kg, 1.0×1014 vg / kg, or 2.0 × 10 14 In another embodiment, the dose is administered at a dose of about 1.85 x 10 vg / kg by intravenous infusion over about 1-2 hours, and the rAAV comprises the scAAVrh74.tMCK7.hSGCA construct nucleotide sequence of SEQ ID NO: 3. In another embodiment, the dose is about 1.85 x 10 based on linearized DNA or plasmid as a quantification standard. 13 vg / kg or 7.41 × 10 13 vg / kg.
[0107] The present disclosure also provides a method for increasing sarcoglycan expression in muscle tissue of a subject, the method comprising administering to a subject a scAAVrh74.tMCK.hSGCA construct comprising a nucleotide sequence at least 90% identical, at least 95% identical, or 99% identical to SEQ ID NO:1 and / or 4.
[0108] The present disclosure also further provides a method of improving muscle function in a subject, the method comprising administering to the subject a construct comprising a nucleotide sequence at least 90% identical, at least 95% identical, or 99% identical to SEQ ID NO:1 and / or 4.
[0109] In some embodiments, the subject suffers from a genetic mutation in a gene encoding a sarcoglycan protein or a muscular dystrophy. In some embodiments, the subject suffers from a genetic mutation in a gene encoding an alpha-sarcoglycan protein.
[0110] In any of the provided methods, the level of alpha-sarcoglycan gene expression in the subject's cells is increased after administration of the scAAVrh74.tMCK7.hSGCA construct compared to the level of alpha-sarcoglycan gene expression before administration of the scAAVrh74.tMCK.hSGCA construct.
[0111] Additionally, in any of the provided methods, expression of the alpha-sarcoglycan gene in cells is detected by measuring alpha-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsied before and after administration of the scAAVrh74.tMCK.hSGCA construct.
[0112] In any of the provided methods, the level of alpha-sarcoglycan protein is increased following administration of the scAAVrh74.tMCK.hSGCA construct. For example, the level of alpha-sarcoglycan protein is increased by at least 33% as detected by measuring alpha-sarcoglycan protein levels by Western blot in muscle biopsied before and after administration of the scAAVrh74.tMCK.hSGCA construct, or the level of alpha-sarcoglycan protein is measured by immunohistochemistry and / or detecting the number of vector genomes per microgram of genomic DNA in muscle biopsies before and after administration of the scAAVrh74.tMCK.hSGCA construct.
[0113] In any of the methods provided herein, serum CK levels in the subject are decreased after administration of the scAAVrh74.tMCK.hSGCA construct compared to serum CK levels before administration of the scAAVrh74.tMCK.hSGCA construct.
[0114] In any of the methods provided herein, the number of alpha-sarcoglycan positive fibers in the muscle tissue of a subject is increased after administration of the scAAVrh74.tMCK.hSGCA construct, compared to the number of alpha-sarcoglycan positive fibers before administration of the ofscAAVrh74.tMCK.hSGCA construct. For example, the number of alpha-sarcoglycan positive fibers is detected by measuring alpha-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsies before and after administration of the scAAVrh74.tMCK.hSGCA construct. For example, the number of alpha-sarcoglycan positive fibers in the muscle tissue of a subject is increased after administration of the scAAVrh74.tMCK.hSGCA construct.
[0115] In any of the methods provided herein, the level of alpha-sarcoglycan in a subject is increased after administration of rAAV compared to the level of alpha-sarcoglycan before administration of the scAAVrh74.tMCK.hSGCA construct. For example, the level of alpha-sarcoglycan is detected by measuring alpha-sarcoglycan protein levels by immunohistochemistry or Western blot in muscle biopsies before and after administration of the scAAVrh74.tMCK.hSGCA construct.
[0116] Another embodiment provides a method of expressing the alpha-sarcoglycan gene in cells of a patient, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In any of the provided methods of expressing the alpha-sarcoglycan gene in cells of a patient, expression of the alpha-sarcoglycan gene in cells of the patient is detected by measuring alpha-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsies before and after administration of the scAAVrh74.tMCK.hSGCA construct. In one embodiment, the alpha-sarcoglycan gene is measured in the patient by detecting more than one rAAV vector genome copy per nucleus. In another embodiment, expression of the alpha-sarcoglycan gene is measured in the subject by detecting the number of vector genomes per microgram of genomic DNA.
[0117] Also provided is a method of reducing serum CK levels in a patient in need thereof comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO:4.
[0118] Methods are provided for increasing alpha-sarcoglycan positive fibers in muscle tissue of a patient, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In any of these methods, the number of alpha-sarcoglycan positive fibers is detected by measuring alpha-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsies before and after administration of the rAAV.
[0119] Another embodiment provides a method of increasing expression of alpha-sarcoglycan in a subject in need thereof, comprising administering to the subject the scAAVrh74.tMCK.hSGCA construct nucleotide sequence of SEQ ID NO: 4. In any of these methods, the level of alpha-sarcoglycan is detected by measuring alpha-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsies before and after administration of the rAAV.
[0120] Also provided is a method of producing recombinant AAV vector particles, comprising culturing cells transfected with any of the recombinant AAV vectors described herein and recovering recombinant AAV particles from the supernatant of the transfected cells. Viral particles comprising any of the recombinant AAV vectors described herein are also contemplated. In one embodiment, a method of producing rAAV comprises transferring an AAV vector plasmid into a host cell. In another embodiment, the recombinant AAV vector particle and / or the AAV vector plasmid comprises a nucleotide sequence that is at least about 65%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, or about 89%, more typically about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% or more identical to SEQ ID NO:8. In another aspect, the present disclosure provides a host cell comprising an AAV vector plasmid comprising the nucleotide sequence of SEQ ID NO:8. In some embodiments, the AAV vector plasmid is stably expressed in the host cell. The host cell stably carrying the AAV vector plasmid can be used to produce rAAV. In one embodiment, the AAV vector plasmid is pAAV.tMCK.hSGCA.KAN plasmid (SEQ ID NO:8).
[0121] Also provided is a method of reducing fibrosis in a mammalian subject in need thereof. In this regard, the method comprises administering a therapeutically effective amount of an AAV vector described herein (or a composition comprising an AAV vector described herein) to a mammalian subject. In some embodiments, the mammalian subject suffers from muscular dystrophy. In one embodiment, the muscular dystrophy is LGMD2D. In some embodiments, administration of an AAV vector described herein (or a composition comprising an AAV vector described herein) reduces fibrosis in muscle tissue of the subject. In one embodiment, the muscle tissue comprises psoas major, diaphragm, triceps brachii, and / or gluteus.
[0122] The term "muscular dystrophy" as used herein refers to disorders that cause gradual loss of strength and muscle mass.Non-limiting examples of muscular dystrophy include congenital muscular dystrophies such as Becker muscular dystrophy, tibial muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, sarcoglycanopathy, congenital muscular dystrophy with partial LAMA2 deficiency, merosin-deficient congenital muscular dystrophy, 1D congenital muscular dystrophy, Fukuyama congenital muscular dystrophy, limb-girdle type 1A muscular dystrophy, limb-girdle type 2A muscular dystrophy, limb-girdle type 2B muscular dystrophy, limb-girdle type 2C muscular dystrophy, and the like. Dystrophies can include limb-girdle muscular dystrophy type 2D, limb-girdle muscular dystrophy type 2E, limb-girdle muscular dystrophy type 2F, limb-girdle muscular dystrophy type 2G, limb-girdle muscular dystrophy type 2H, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2I, limb-girdle muscular dystrophy type 2J, limb-girdle muscular dystrophy type 2K, limb-girdle IC muscular dystrophy, ankylosing spinal muscular dystrophy with simple epidermolysis bullosa, oculopharyngeal muscular dystrophy, Ullrich congenital muscular dystrophy, and Ullrich scleroatonic muscular dystrophy.In some embodiments, the subject suffers from limb-girdle muscular dystrophy type 2D (LGMD2D).
[0123] As used herein, the term "fibrosis" refers to the excessive or unregulated deposition of extracellular matrix (ECM) components and abnormal repair processes in tissues following injury, including skeletal muscle, cardiac muscle, liver, lung, kidney, and pancreas. Deposited ECM components include collagen (e.g., collagen 1, collagen 2, or collagen 3) and fibronectin.
[0124] In another aspect, described herein is a method of increasing alpha-sarcoglycan positive fibers in muscle tissue, fiber diameter size, eccentric contraction in muscle, muscle strength, and / or alpha-sarcoglycan expression in a mammal, comprising administering to the mammalian subject a therapeutically effective amount of an AAV vector described herein (or a composition comprising an AAV vector described herein). Also described herein is a method of decreasing fibrosis, central nucleation, CK levels, and / or collage deposition in a subject, comprising administering to the subject a therapeutically effective amount of an AAV vector described herein (or a composition comprising an AAV vector described herein).
[0125] In any of the methods of the invention, the subject may be suffering from a muscular dystrophy, such as limb-girdle muscular dystrophy or any other dystrophin-related muscular dystrophy. In one embodiment, the muscular dystrophy is LGMD-2D.
[0126] Also provided are methods of treating muscular dystrophy in a mammalian subject, comprising administering to the mammalian subject a therapeutically effective amount of an AAV vector described herein (or a composition comprising an AAV vector described herein). In some embodiments, the muscular dystrophy is limb-girdle muscular dystrophy.
[0127] In any of the methods of the invention, the rAAV is administered by intramuscular or intravenous injection. In addition, in any of the methods of the invention, the rAAV is administered systemically, such as parenterally by injection, infusion, or implantation.
[0128] The compositions of the invention are formulated for intramuscular or intravenous injection. In addition, the compositions of the invention are formulated for systemic administration, such as parenteral administration by injection, infusion, or implantation.
[0129] In addition, any of the compositions is formulated for administration to a subject suffering from muscular dystrophy (e.g., limb-girdle muscular dystrophy or any other dystrophin-related muscular dystrophy).In some embodiments, the composition may further comprise a second recombinant AAV vector expressing alpha-sarcoglycan, or a second recombinant AAV vector comprising the polynucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4.
[0130] In any of the uses of the present invention, the medicament is formulated for intramuscular or intravenous injection.In addition, in any of the uses of the present invention, the medicament is formulated for systemic administration, such as parenteral administration by injection, infusion or implantation.In addition, any of the medicaments can be prepared for administration to subjects suffering from muscular dystrophy (e.g., limb-girdle muscular dystrophy or any other dystrophin-related muscular dystrophy).In some embodiments, the medicament can further comprise a second recombinant AAV vector that expresses alpha-sarcoglycan, or a second recombinant AAV vector that comprises the polynucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4.
[0131] The preceding paragraphs are not intended to define all aspects of the invention, and additional aspects are described in other sections, such as the detailed description. It is understood that the entire document is intended to relate as a unified disclosure, and that all combinations of features described herein are considered, even if the combinations of features are not found together in the same sentence, paragraph, or section of this document. The invention includes, as an additional aspect, all embodiments of the invention that are somewhat narrower in scope than the variations defined in the specific paragraphs above. For example, if a particular aspect of the invention is described as a genus, it should be understood that each member of the genus is an aspect of the invention individually.
[0132] AAV The recombinant AAV genome of the present invention comprises the nucleic acid molecule of the present invention and one or more AAV ITRs flanking the nucleic acid molecule.The AAV DNA in the rAAV genome can be from any AAV serotype from which the recombinant virus can be derived, including but not limited to AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, and AAV rh.74.The generation of pseudotyped rAAV is disclosed, for example, in WO01 / 83692.Other types of rAAV mutants are also contemplated, such as rAAV with capsid mutations.
[0133] The DNA plasmid of the present invention comprises a rAAV genome. The DNA plasmid is introduced into a cell that is permissive for infection with AAV's helper virus (e.g., adenovirus, E1-deleted adenovirus, or herpesvirus) for the incorporation of the rAAV genome into infectious viral particles. The technology of producing rAAV particles is standard in the art, in which the packaged AAV genome, rep and cap genes, and helper virus functions are provided to the cell. The production of rAAV requires the presence of the following components in a single cell (referred to herein as a packaging cell): the rAAV genome, the AAV rep and cap genes separated from (i.e., not present in) the rAAV genome, and the helper virus functions. The AAV rep and cap genes can be from any AAV serotype from which a recombinant virus can be derived, and can be from an AAV serotype different from the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV rh10, and AAV rh.74. The generation of pseudotyped rAAV is disclosed, for example, in WO2001 / 083692, which is incorporated herein by reference in its entirety.
[0134] The method of generating packaging cells is to create a cell line that stably expresses all the components required for the production of AAV particles. For example, a plasmid (or multiple plasmids) containing a rAAV genome lacking AAVrep and cap genes, AAVrep and cap genes separated from the rAAV genome, and a selectable marker such as a neomycin resistance gene is integrated into the genome of the cell. The AAV genome is introduced into a bacterial plasmid by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing a restriction endonuclease cleavage site (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantage of this method is that the cells are selectable and suitable for large-scale production of rAAV. Other examples of suitable methods use adenovirus or baculovirus rather than plasmids to introduce the rAAV genome and / or the rep and cap genes into packaging cells.
[0135] General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539, and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072 (1984), Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984), Tratschin et al., Mol. Cell. Biol. 5:3251 (1985), McLaughlin et al., J. Virol., 62:1963 (1988), and Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828), U.S. Pat. No. 5,173,414, WO95 / 13365 and corresponding U.S. Pat. No. 5,658,776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO99 / 11764, Perrin et al. (1995) Vaccine 13:1244-1250, Paul et al. (1993) Human Gene Therapy 4:609-615, Clark et al. (1996) Gene Therapy 3:1124-1132, U.S. Patent No. 5,786,211, U.S. Patent No. 5,871,982, and U.S. Patent No. 6,258,595. The foregoing documents are incorporated herein by reference in their entireties, with particular emphasis on the portions of the documents relating to rAAV production.
[0136] Therefore, the present invention provides a packaging cell that produces infectious rAAV.In one embodiment, the packaging cell can be a stably transformed cancer cell, such as HeLa cell, 293 cell, and PerC.6 cell (similar 293 line).In another embodiment, the packaging cell is a cell that is not a transformed cancer cell, such as low-passage 293 cell (human fetal kidney cell transformed with adenovirus E1), MRC-5 cell (human fetal fibroblast), WI-38 cell (human fetal fibroblast), Vero cell (monkey kidney cell), and FRhL-2 cell (rhesus fetal lung cell).
[0137] Recombinant AAV of the invention (i.e., infectious, encapsidated rAAV particles) comprise a rAAV genome. Embodiments include, but are not limited to, a rAAV designated pAAV.tMCK.hSCGA, which comprises the polynucleotide sequence set forth in SEQ ID NO:3.
[0138] rAAV can be purified by standard methods in the art, such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper viruses are known in the art, including, for example, those disclosed in Clark et al., Hum. Gene Ther., 10(6): 1031-1039 (1999), Schenpp and Clark, Methods Mol. Med., 69: 427-443 (2002), U.S. Patent No. 6,566,118, and WO98 / 09657.
[0139] In another embodiment, the present invention contemplates a composition comprising the rAAV of the present invention. The compositions described herein comprise rAAV in a pharma- ceutically acceptable carrier. The compositions may also include other components, such as diluents and adjuvants. Acceptable carriers, diluents, and adjuvants are non-toxic to recipients, preferably inert at the dosages and concentrations used, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; proteins such as low molecular weight polypeptides, serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or non-ionic surfactants such as Tween, Pluronics, or polyethylene glycol (PEG).
[0140] The titer of the rAAV administered in the methods of the invention will vary depending, for example, on the particular rAAV, the method of administration, the treatment goal, the individual, and the cell type being targeted, and can be determined by standard methods in the art. The titer of the rAAV is approximately 1 x 10 per ml. 6 , about 1×10 7 , about 1×10 8 , about 1×10 9 , about 1×10 10 , about 1×10 11 , about 1×10 12 , about 1×10 13 ~Approx. 1×10 14 Dosages may range from 100 mg to 1000 mg of DNase resistant particles (DRP), or more. Dosages may be expressed in units of viral genomes (vg) as measured by qPCR.
[0141] Methods of transducing target cells with rAAV in vivo or in vitro are contemplated by the present invention. In vivo methods include administering an effective dose or effective doses of a composition comprising the rAAV of the present invention to an animal (including a human) in need thereof. If the dose is administered before the onset of the disorder / disease, the administration is prophylactic. If the dose is administered after the onset of the disorder / disease, the administration is therapeutic. In an embodiment of the present invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder / disease state to be treated, slows or prevents progression to the disorder / disease state, reduces the extent of the disease, causes remission (partial or complete) of the disease, and / or prolongs survival. An example of a disease contemplated for prevention or treatment by the method of the present invention is muscular dystrophy, such as limb-girdle muscular dystrophy. Thus, provided is a method of transducing target cells with rAAV scAAVrh74.tMCK.hSGCA, comprising the nucleotide sequence of SEQ ID NO:4.
[0142] In another embodiment, the disclosure provides a method for generating rAAV scAAVrh74.tMCK.hSGCA, comprising introducing an AAV vector plasmid into a host cell. Methods for introducing DNA into a host cell are known in the art, including, but not limited to, transfection, infection, transformation, electroporation, and transduction. In one embodiment, the vector plasmid comprises a nucleotide sequence that is at least about 65%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, or about 89%, more typically about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% or more identical to SEQ ID NO:8. In another embodiment, the vector plasmid comprises a nucleotide sequence that is at least 90%, 95%, or 99% identical to SEQ ID NO:8. In another embodiment, the vector plasmid comprises the nucleotide sequence of SEQ ID NO:8. In another aspect, the present disclosure provides a host cell comprising an AAV vector plasmid comprising the nucleotide sequence of SEQ ID NO:8. In some embodiments, the AAV vector plasmid is stably expressed in the host cell. The host cell stably carrying the AAV vector plasmid can be used to produce rAAV. In one embodiment, the AAV vector plasmid is a pAAV.tMCK.hSGCA.KAN plasmid.
[0143] In one embodiment, the vector plasmid comprises a nucleotide sequence that is at least about 65%, about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, or about 89%, more typically about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% or more identical to SEQ ID NO:1, 4, or 8.
[0144] In one embodiment, the vector plasmid comprises a nucleotide sequence that is at least 90%, 95%, or 99% identical to SEQ ID NO: 1, 4, or 8. In one embodiment, the vector plasmid comprises the nucleotide sequence of SEQ ID NO: 8. The method of generating rAAV, in one embodiment, further comprises transfecting a packaging plasmid and / or a helper virus into the host cell. The packaging plasmid, in some embodiments, comprises an AAV rep and / or cap gene operably linked to a promoter. In one embodiment, the promoter is an AAV transcription promoter. In one embodiment, the host cell is a packaging cell. In one embodiment, the packaging cell comprises a stably integrated AAVcap gene. In another embodiment, the packaging cell comprises a stably integrated AAVrep gene.
[0145] As used herein, the term "host cell" refers to a cell that can be used to express an exogenous DNA sequence. Non-limiting examples of host cells include microorganisms, yeast cells, insect cells, and / or mammalian cells. Host cells can be used as recipients of AAV helper constructs, packaging plasmids, AAV vector plasmids, accessory function vectors, or other DNA. The term as used herein encompasses the progeny of the original cell after expression of the exogenous DNA sequence in the original host cell. Non-limiting examples of host cells for AAV production include Sf9 insect cells and HEK293T cells. AAV vector plasmids can be introduced into host cells (e.g., Sf9 or 293T) by infection (virus or baculovirus), transient transfection using reagents (e.g., liposomes, calcium phosphate), or physical means (e.g., electroporation), or other means known in the art. In another embodiment, host cell lines are stably integrated with the rAAV plasmid in their genome. Such stable cell lines can be established by incorporating a selection marker into the vector plasmid.
[0146] In one embodiment, the host cell is a packaging cell for producing AAV viral particles.Thus, in another aspect, the present disclosure provides a host cell comprising an AAV vector plasmid comprising a nucleotide sequence at least 90%, 95%, or 99% identical to SEQ ID NO:8.In one embodiment, the AAV vector plasmid comprises the nucleotide sequence of SEQ ID NO:8.In another embodiment, the host cell comprises the nucleotide sequence of SEQ ID NO:1, 4, or 8.
[0147] Combination therapy is also contemplated by the present invention. Combination therapy as used herein includes simultaneous or sequential therapy. Combination of the method of the present invention with standard medical treatment (e.g., steroids, corticosteroids, and / or glucocorticoids, including but not limited to one or more of prednisone, prednisolone, and deflazacort) is specifically contemplated, as well as combination with novel therapy. In this respect, this combination includes administering to the subject one or more steroids, corticosteroids, and / or glucocorticoids, including but not limited to one or more of prednisone, prednisolone, and deflazacort, before administering to the subject the rAAV of the method of the present invention, simultaneously with administering to the subject the rAAV, or after administering to the subject the rAAV.
[0148] In related embodiments of the combination therapy contemplated by the present invention, glucocorticoids include, but are not limited to, beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or triamcinolone.
[0149] It is recognized that antigen-specific T cell responses can occur in subjects administered rAAV vectors. This is an expected response 2-4 weeks after gene transfer. One possible outcome to such antigen-specific T cell responses is clearance of the transduced cells and loss of transgene expression. To dampen the host's immune response to rAAV-based therapy, prior to treatment, e.g., 24 hours before the treatment procedure, subjects can be started on prophylactic presonisone or equivalent glucocorticoids orally at approximately 1 mg / kg / day, with a maximum dose of 60 mg / day. If necessary, equivalent glucocorticoids can also be administered intravenously at a dose of approximately 1 mg / kg / day. Treatment lasts approximately one month. A tapering protocol of the amount of presonisone or equivalent glucocorticoid can be implemented based on the individual subject's immune response to gene transfer, assessed by ELISpot assay and by liver function monitoring with GGT.
[0150] A therapeutically effective amount of rAAV vector is approximately 1.0 × 10 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 5×10 13 vg / kg ~ approx. 2×10 14 vg / kg, or approximately 2.0 × 10 13 vg / kg ~ approx. 3.0×10 14 In another embodiment, the dose is about 5.0×10 13 vg / kg, approximately 1.0×10 14 vg / kg, or approximately 2.0 × 10 14 In another embodiment, the dose is 5.0×10 13 vg / kg, 1.0×10 14 vg / kg, or 2.0 × 10 14 vg / kg. The present invention is also contemplated to include compositions comprising rAAV vectors in these ranges.
[0151] Dosage may be expressed in units of viral genome (vg). The titer of rAAV may be determined by a supercoiled DNA or plasmid quantification standard or a linearized DNA or plasmid quantification standard. The titer or dosage of the AAV vector may vary based on the physical form of the plasmid or DNA as the quantification standard. For example, the titer or dosage value may vary based on a supercoiled standard qPCR titration method or a linearized standard qPCR titration method. In one embodiment, the dosage in the present disclosure is based on supercoiled DNA or plasmid as the quantification standard. In another embodiment, the dosage in the present disclosure is based on linearized DNA or plasmid as the quantification standard. Thus, in one embodiment, a therapeutically effective amount of a rAAV vector is about 1.0×10 based on supercoiled DNA or plasmid as the quantification standard. 12 vg / kg ~ approx. 2.0×10 15 vg / kg, approx. 5×10 12 vg / kg ~ approx. 1.0×10 15 vg / kg, approximately 1.0×10 13 vg / kg ~ approx. 5.0×10 14 vg / kg, approx. 5×10 13 vg / kg ~ approx. 2×10 14 vg / kg, or approximately 2.0 × 10 13 vg / kg ~ approx. 3.0×10 14 In another embodiment, the dose is about 5.0×10 rAAV in the range of 1000×g / kg, based on supercoiled DNA or plasmid as a quantification standard. 13 vg / kg, approximately 1.0×10 14 vg / kg, or approximately 2.0 × 10 14 In another embodiment, the dose is 5.0×10 vg / kg, based on supercoiled DNA or plasmid as a quantitative standard. 13 vg / kg, 1.0×10 14 vg / kg, or 2.0 × 10 14 vg / kg.
[0152] In another embodiment, a therapeutically effective amount of a rAAV vector is about 1.0×10 based on linearized DNA or plasmid as a quantification standard. 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.5×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.6×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.8×10 13 vg / kg ~ approx. 8.0×10 13 vg / kg, approximately 1.2×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, approximately 1.4×10 13 vg / kg ~ approx. 7.4×10 13 vg / kg, approximately 1.9×10 13 vg / kg ~ approx. 7.5×10 13 vg / kg, or approximately 1.8 × 10 13 vg / kg ~ approx. 8.0×10 13 For example, a therapeutically effective amount of a rAAV vector is approximately 1.85×10 based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg or 7.41 × 10 13 Dose is in vg / kg.
[0153] In one embodiment, 5.0×10 based on supercoiled DNA or plasmid as a quantitative standard 13 The dose is 1.85 × 10 vg / kg based on linearized DNA or plasmid as a quantitative standard. 13 In another embodiment, the dose is equivalent to a 2.0×10 14 The dose is 7.41 × 10 vg / kg based on linearized DNA or plasmid as a quantitative standard. 13 vg / kg. Thus, in another embodiment, the quantification standard is about 1.85×10 13vg / kg or 7.41 × 10 13 vg / kg.
[0154] Administration of an effective dose of the composition may be by routes standard in the art, including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. The administration route(s) and serotype(s) of the AAV components (specifically, AAV ITRs and capsid proteins) of the rAAV of the present invention may be selected and / or adapted by those skilled in the art taking into account the infection and / or disease state to be treated, and the target cell / tissue(s) expressing α-sarcoglycan.
[0155] The present invention provides for local and systemic administration of effective doses of the rAAV and compositions of the present invention.For example, systemic administration refers to administration into the circulatory system so that the whole body is affected.Systemic administration includes enteral administration, such as absorption through the gastrointestinal tract, and parenteral administration by injection, infusion, or implantation.
[0156] In particular, the actual administration of the rAAV of the present invention can be achieved by using any physical method that transports the rAAV recombinant vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, injection into muscle, injection into the bloodstream, and / or direct injection into the liver. Simply resuspending rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on the carriers or other components that may be co-administered with rAAV (although compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified to target rAAV to a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference.
[0157] The pharmaceutical composition can be prepared as an injectable formulation or as a local formulation delivered to muscle by transdermal delivery. Numerous formulations for both intramuscular injection and transdermal delivery have been developed and can be used in the practice of the present invention. The rAAV can be used with any pharma- ceutically acceptable carrier for ease of administration and handling. Thus, in another aspect, the present application relates to a formulation comprising an rAAV comprising a capsid derived from AAVrh74, a buffer, an ionic strength agent, and a surfactant. In one embodiment, the rAAV is administered at a concentration of about 1.0×10 12 vg / kg ~ approx. 5.0×10 14 In another embodiment, the rAAV is at a concentration of about 5.0×10 12 vg / kg~1.0×10 14 In another embodiment, the rAAV is at a concentration of about 5×10 13 vg / kg, approximately 1×10 14 vg / kg, and / or approximately 2 × 10 14vg / kg. In one embodiment, the dosage is based on supercoiled DNA or plasmid as a quantification standard. In one embodiment, the rAAV is a scAAVrh74.tMCK.hSGCA vector. In one embodiment, the buffer comprises one or more of Tris, Tricine, Bis-Tricine, HEPES, MOPS, TES, TAPS, PIPES, and CAPS. In another embodiment, the buffer comprises Tris at a pH of 8.0 at a concentration of about 5 mM to about 40 mM. In one embodiment, the buffer comprises Tris at a pH of 8.0 at about 20 mM. In one embodiment, the ionic strength agent comprises one or more of potassium chloride (KCl), potassium acetate, potassium sulfate, ammonium sulfate, ammonium chloride (NH4Cl), ammonium acetate, magnesium chloride (MgCl2), magnesium acetate, magnesium sulfate, manganese chloride (MnCl2), manganese acetate, manganese sulfate, sodium chloride (NaCl), sodium acetate, lithium chloride (LiCl), and lithium acetate. In one embodiment, the ionic strength agent comprises MgCl2 at a concentration of about 0.2 mM to about 4 mM. In another embodiment, the ionic strength agent comprises NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCl2 at a concentration of about 0.2 mM to about 4 mM and NaCl at a concentration of about 50 mM to about 500 mM. In another embodiment, the ionic strength agent comprises MgCl2 at a concentration of about 1 mM and NaCl at a concentration of about 200 mM. In one embodiment, the surfactant comprises one or more of a sulfonate, sulfate, phosphonate, phosphate, poloxamer, and cationic surfactant. In one embodiment, the poloxamer comprises one or more of poloxamer 124, poloxamer 181, poloxamer 184, poloxamer 188, poloxamer 237, poloxamer 331, poloxamer 338, and poloxamer 407. In one embodiment, the surfactant comprises a poloxamer at a concentration of about 0.00001% to about 1%. In another embodiment, the surfactant comprises poloxamer 188 at a concentration of about 0.001%. For intramuscular injection purposes, solutions in adjuvants such as sesame or peanut oil, or aqueous propylene glycol solutions, and sterile aqueous solutions can be used.Such aqueous solutions can be buffered if necessary, and the liquid diluent is first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, as well as in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily available by standard techniques well known to those skilled in the art.
[0158] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating agent such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0159] Sterile injectable solution is prepared by incorporating the required amount of rAAV into a suitable solvent, together with various other components as listed above as necessary, and then sterilizing by filtration.Generally, dispersion is prepared by mixing sterilized active ingredient into a sterile vehicle that contains basic dispersion medium and other required components from those listed above.In the case of sterile powder for preparing sterile injectable solution, the preferred method of preparation is vacuum drying and freeze-drying technology, which produces powder of active ingredient plus any additional desired components from their solution that has been previously sterilized and filtered.
[0160] Transduction with rAAV can also be performed in vitro. In one embodiment, the desired target muscle cells are removed from the subject, transduced with rAAV, and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used if they do not generate an inappropriate immune response in the subject.
[0161] Suitable methods for transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced in vitro, for example by combining rAAV with muscle cells in a suitable medium and screening for cells with the DNA of interest using conventional techniques such as Southern blot and / or PCR, or using a selectable marker. The transduced cells can then be formulated into a pharmaceutical composition, and the composition can be introduced into a subject by a variety of techniques, such as by intramuscular, intravenous, subcutaneous, and intraperitoneal injection, or by injection into smooth and cardiac muscles, for example, using a catheter.
[0162] Transduction of cells with the rAAV of the present invention results in sustained expression of alpha-sarcoglycan. Thus, the present invention provides methods for administering / delivering rAAV expressing alpha-sarcoglycan to a mammalian subject, preferably a human. These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands) with one or more rAAV of the present invention. Transduction can be performed with gene cassettes that contain tissue-specific regulatory elements. For example, one embodiment of the present invention provides a method of transducing muscle cells and muscle tissue that is directed by muscle-specific regulatory elements, including, but not limited to, those from the actin and myosin gene families, such as the myoD gene family [see Weintraub et al., Science, 251:761-766 (1991)], muscle cell-specific enhancer binding factor MEF-2 [Cserjesi and Olson, Mol. Cell. Biol., 11:4854-4862 (1991)], regulatory elements from the human skeletal actin gene [Muscat et al., Mol. Cell. Biol., 7:4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [Johnson et al. al., Mol. Cell. Biol., 9:3393-3399 (1989)], as well as regulatory elements from the mouse creatine kinase enhancer (mCK) element, the fast skeletal troponin C gene, the slow cardiac troponin C gene, and the slow troponin I gene, hypoxia-inducible nuclear factor (Semenza et al., Proc. Natl. Acad. Sci. USA 88:5680-5684 (1991)), steroid-inducible elements and promoters, including glucocorticoid response elements (GREs) (see Mader and White, Proc. Natl. Acad. Sci. USA, 90:5603-5607 (1993)), and other regulatory elements.
[0163] Since muscle tissue is not a vital organ and is easily accessible, it is an attractive target for in vivo DNA delivery. The present invention contemplates sustained expression of miRNA from transduced myofibrils.
[0164] By "muscle cell" or "muscle tissue" is meant a cell or group of cells derived from any type of muscle (e.g., skeletal and smooth muscle derived from the digestive tract, bladder, blood vessels, or heart tissue). Such muscle cells can be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyoblasts.
[0165] The term "transduction" is used to refer to the administration / delivery of a polynucleotide of interest (e.g., a polynucleotide sequence encoding alpha-sarcoglycan) to a recipient cell either in vivo or in vitro via a described replication-deficient rAAV, resulting in expression of alpha-sarcoglycan by the recipient cell.
[0166] Thus, also described herein is a method of administering an effective dose (or doses administered essentially simultaneously or at an interval) of an rAAV encoding alpha-sarcoglycan to a mammalian subject in need thereof.
[0167] All publications and patents mentioned in this specification are incorporated herein by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, this application will control, including any definitions herein. The numerical ranges described include each integer value within each range, including the minimum and maximum integers stated.
[0168] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. EXAMPLES
[0169] Preclinical studies using AAVrh74.tMCK.hSCGA are described in International Patent Publication No. WO2013 / 078316, and U.S. Patent Nos. 9,434,928 and 10,105,453, which are incorporated by reference in their entireties.
[0170] Example 1 material and method Animal models All procedures were approved by the Research Institute at Nationwide Children's Hospital Institutional Animal Care and Use Committee. - / - ) Mice were bred and maintained as homozygous animals under standard conditions at the Animal Resources Core of the Research Institute at Nationwide Children's Hospital. Mice were maintained on a Teklad Global Rodent Diet (3.8% dietary fiber, 18.8% protein, 5% fat diet) with a 12:12 h dark:light cycle. All animals were housed in standard mouse cages and had free access to food and water.
[0171] Genotype Using DNA genotyping, sgca - / -Mice were identified. DNA from tail clippings was isolated and analyzed by polymerase chain reaction (PCR) using OneTaq DNA polymerase (New England Biolabs, Ipswich, MA). A series of primers were used in PCR analysis to determine the α-SG knockout status. The following primers and conditions were used: Intron1 (CAGGGCTGGGAGCTGGGTTCTG; SEQ ID NO: 9), mutant primer-Intron3 (CCCAGGGCCTTGATGCCT; SEQ ID NO: 10), and NEOTR (GCTATCAGGACATAGCGTTGGCTA; SEQ ID NO: 11). Thirty cycles of reactions were performed on genomic DNA under the following conditions: 94°C for 5 minutes, 94°C for 1 minute, 64°C for 1 minute, 72°C for 2.5 minutes, and 72°C for 7 minutes.
[0172] α-SG gene construct The scAAVrh74.tMCK.hSGCA transgene cassette was generated by inserting a tMCK expression cassette driving a codon-optimized human α-SGc DNA sequence (human cDNA, Genbank accession number U08895) into the self-complementary vector backbone pHpa7 using the adeno-associated virus (AAV) vector DNA plasmid pAAV.tMCK.aSG-neo. The only viral sequences contained in this vector are the inverted terminal repeats of AAV2, which are required for both viral DNA replication and packaging of the rAAV vector genome. One of the inverted terminal repeats (ITRs) has a targeted deletion of the terminal resolution site (TRS) to restrict replication from this ITR, promoting the generation of a dimeric replicative form for self-complementary vector packaging. The AAVrh74 virus has been proven safe and highly efficient to transduce muscle across the vascular barrier in mice, non-human primates (NHPs), and humans.
[0173] Vector production Recombinant AAV, (sc)rAAVrh74.tMCK.hSGCA, was generated by triple transfection. A qPCR-based titration method was used to determine the encapsidated vg titer utilizing a Prism 7500 Fast Taqman detector system (PE Applied Biosystems). The construct contains a chimeric intron to drive high levels of expression. The chimeric intron consists of a 5' donor site from the first intron and branch point of the human β-globin gene, and a 3' splice acceptor site from an intron located between the leader and body of the immunoglobulin gene heavy chain variable region. The rAAV also contains a synthetic SV40 polyadenylation signal, used for efficient transcription termination. A schematic of the expression cassette is shown in Figure 1 below. The vector was produced using the human alpha-sacroglycan (α-SG) gene flanked by AAV2 ITR sequences and encapsidated into the AAVrh74 virion. The construct contains the tMCK immediate early promoter / enhancer (GenBank accession number M21390) and uses the β-globin intron for high level expression.
[0174] Gene delivery Systemic delivery was achieved by injection of vector into the tail vein of sgca− / − mice. Mice were injected with 1 × 10 of scAAVrh74.tMCK.hSGCA diluted in lactated Ringer's solution in a volume of 200–250 μL using a 30-gauge ultrafine insulin syringe. 12 vg, 3×10 12 vg, or 6×10 12 Total dose in vg (range 13-20 g mice, based on a 20 g mouse each) based on supercoiled DNA or plasmid as quantification standard, 5 × 10 13 vg / kg, 1×10 14 vg / kg, and 2 × 10 14 All treated mice were injected at 4-5 weeks of age and euthanized 12 weeks after injection. In another embodiment, the dose is approximately 1.85 x 10 13 vg / kg or 7.41 × 1013 vg / kg.
[0175] Serum creatine kinase measurement Creatine kinase levels were measured in wild-type C57BL / 6 mice (n=6), sgca mice treated with vehicle (lactated Ringer's solution), and control mice (n=10). - / - Mice (n=6), and sgca treated with scAAVrh74.tMCK.hSGCA - / - Creatine kinase was measured in serum from mice (n=6 per dose) using the creatine kinase SL assay and corresponding manufacturer's protocol (Sekisui Diagnostics, Charlottetown, PE, Canada) (catalog no. 326-10). Briefly, 25 μL of serum was mixed with 1 mL of working reagent and added to a cuvette. The kinetic assay was set up on a spectrophotometer to measure absorbance at 340 nm every 30 seconds for 180 seconds. Creatine kinase levels were calculated using the absorbance readings and the formula listed below. U / L=[ΔAbs. / min)*1.025*1000] / [1*6.22*0.025]=(ΔAbs. / min)*6592
[0176] Diaphragmatic tetanus for functional assessment Mice were euthanized and the diaphragm (DIA) was dissected with the rib attachment and central tendon intact and placed in KH buffer. 2-4 mm wide sections of the DIA were isolated. The DIA strip was tied securely at the tendon center with braided surgical silk (6 / 0, Surgical Specialties, Reading, PA) and sutured through a portion of the rib attached to the distal end of the strip. Each muscle was transferred to a water bath filled with oxygenated KH solution maintained at 37 °C. The muscle was aligned horizontally and tied directly between a fixation pin and a dual-mode force transducer servomotor (305C, Aurora Scientific, Aurora, Ontario, Canada). Two platinum plate electrodes were positioned in the organ bath adjacent to the muscle length. The muscle was stretched to the optimal length for measurement of twitch contractions and then allowed to rest for 10 min before initiating the tetanic protocol. Once the muscle is stable, it is set to an optimal length of 1 g and subjected to a warm-up consisting of three 1 Hz twitches every 30 seconds, followed by three 150 Hz twitches every 1 minute.After a 3-minute rest period, the DIA is stimulated at 20, 50, 80, 120, 150, and 180 Hz for 250 milliseconds each, with a 2-minute rest period between each stimulation, to determine maximum tetanic force.Muscle length and weight are measured.Force is normalized to muscle weight and length.
[0177] Tibialis Anterior (TA) Tetanus for Functional Assessment The TA evaluation procedure followed the protocol listed in Hakim et al., Methods Mol Biol;709:75-89(2011). Mice were anesthetized via intraperitoneal injection using a ketamine / xylazine mixture (100mg / kg and 10mg / kg, respectively). Under a dissecting scope, the skin of the hind limb was removed to expose the TA muscle and patella. A double square was tied with a 4-0 suture around the patellar tendon. The TA distal tendon was then incised and a double square was tied with a 4-0 suture around the tendon as close to the muscle as possible, and then the tendon was cut. The exposed muscle was moistened with saline at all times. The mouse was then transferred to a thermo-controlled platform and maintained at 37°C. The knee was fixed to a metal pin with the patellar tendon suture and the distal TA tendon suture was fixed to the level arm of a force transducer (Aurora Scientific, Aurora, Canada). To stimulate the sciatic nerve, an electrode was placed close to the sciatic nerve. Once the muscle was stabilized, the resting tension was set to the length at which the twitch contraction was maximized (optimal length). After a 3-minute rest period, the TA was stimulated at 50, 100, 150, and 200 Hz with a 1-minute rest period between each stimulation. After a 5-minute rest period, the muscle was subjected to a series of 10 isometric contractions, which were generated at 1-minute intervals with a 10% stretch-relength procedure. After the eccentric contraction, the mice were euthanized, and the TA muscles were dissected, weighed, and frozen for analysis.
[0178] Immunofluorescence Frozen sections (12 μm thick) of TA, gastrocnemius (GAS), quadriceps (QD), psoas (PSOAS), gluteus (GLUT), triceps (TRI), DIA, and heart (HRT) muscles were subjected to immunofluorescence staining for the hSGCA transgene. Sections were incubated with rabbit monoclonal α-SG primary antibody (Abcam, Cambridge, UK, catalogue no. ab189254) at a dilution of 1:100. Four random 20x images covering four different quadrants of muscle sections were taken using a Zeiss (Germany) AxioCam MRC5 camera. The percentage of positive fibers for α-SG staining compared to controls was determined for each image and averaged for each muscle. Positive α-SG fiber expression was defined as fiber staining at least 30% brighter than vehicle-treated sgca- / - controls.
[0179] Western blot analysis Samples from wild-type C57BL / 6 mice, vehicle-treated sgca- / - mice, and vector-administered sgca- / - mice were used for each Western blot. For hSGCA blots, a 1:10,000 dilution of rabbit monoclonal α-SG antibody (Abcam, catalog no. ab189254) and a 1:5,000 dilution of mouse monoclonal α-actinin antibody (Sigma-Aldrich, catalog no. A7811) were used at a dilution of 1:1,000 of rabbit monoclonal mouse vinculin antibody (Invitrogen, catalog no. 70062) were also used. Secondary horseradish peroxidase antibodies, anti-mouse (Millipore, catalog no. AP308P) and anti-rabbit (Life Technologies, catalog no. 656120), were used to enhance chemiluminescence immunodetection. Quantification of Western blots was performed by densitometry using ImageQuantTL 1D 8.1.0 (GE Healthcare Life Sciences).
[0180] Morphometric analysis Hematoxylin & Eosin (H&E) staining was performed on 12 μm thick muscle cryosections from 16-17 week old wild type C57BL / 6 mice (n=6), vehicle treated sgca- / - mice (n=6), and 16-17 week old scAAVrh74.tMCK.hSGCA treated sgca- / - mice (n=6 per dose) for analysis. The percentage of myofibers with central nuclei was determined in TA, GAS, QD, GLUT, PSOAS, and TRI muscles. Additionally, myofiber diameter was measured in TA, GAS, QD, TRI, and PSOAS muscles. Four random 20x images per muscle from each animal were taken with a Zeiss AxioCam MRC5 camera. Centrally nucleated fibers were quantified using National Institutes of Health's ImageJ software, and fiber diameter was measured using Zeiss Axiovision LE4 software.
[0181] Quantitative polymerase chain reaction (PCR) analysis of biodistribution Taqman quantitative PCR was performed to quantify the number of vector genome copies present in targeted and non-targeted contralateral muscles, as well as non-targeted organs, as previously described. A vector-specific primer-probe set was used to amplify sequences in the intronic region immediately downstream of the unique tMCK promoter located within the scAAVrh.74.tMCK.hSGCA transgene cassette. The following primers and probes were used in this study: tMCK intron forward primer 5'-ACC CGA GAT GCC TGG TTA TAA TT-3', tMCK intron reverse primer 5'-TCC ATG GTG TAC AGA GCC TAA GAC-3', and tMCK intron probe 5'-FAM-CTG CTG CCT GAG CCT GAG CGG TTA C- IABkFQ-3' (Integrated DNA Technologies). Copy numbers are reported as vector genomes per microgram of genomic DNA.
[0182] Picrosirius red staining and collagen quantification Picrosirius red staining was performed to determine the level of collagen deposition in muscle tissue. Staining was performed on 12 µm thick frozen sections from GLUT, PSOAS, TRI, and DIA muscles of 16-17 week old wild type C57BL / 6 (n=6), vehicle treated sgca- / - (n=6), and 16-17 week old scAAVrh74.tMCK.hSGCA treated sgca- / - mice (n=6 per dose). Four 20x images were taken per muscle of each mouse, and the amount of collagen deposition was measured using the ImageJ software program. The average collagen percent for each muscle was calculated for all groups.
[0183] Laser monitoring of open field cage activity Open field activity chambers were used to determine the overall activity of experimental mice. Wild-type C57BL / 6 (n=6) and untreated sgca mice were - / - (n=6) 16-17 week old mice from the control group were treated with scAAVrh74.tMCK.hSGCA at 16-17 weeks of age. - / -Mice (n=6 per dose) were subjected to analysis. All mice were tested at the same time each day, from early morning to late evening cycles when mice are most active. All mice were tested in isolation rooms, under dim light and by the same caretakers each time. Mice were also tested that were not individually housed, to reduce anxiety and minimize variable behaviors that may affect the mice's normal behavior and therefore the results of the assay. Mouse behavior was monitored using a Photobeam Activity System (San Diego Instruments, San Diego, CA). This system uses a grid of invisible infrared light beams that traverse the front, back, left and right sides of the animal chamber to monitor the position and movement of the mouse in the xyz plane. Activity was recorded in 1-hour cycles with 5-minute intervals. Mice were acclimated to the activity testing room for 1-hour sessions several days before data acquisition began. Mice were tested in individual chambers in groups of 4. Testing equipment was cleaned after each use to reduce reactive variable behaviors of mice that may alter the results. Data were transferred to a Microsoft Excel worksheet and all calculations were performed within the Excel program. Individual ray breaks for movement in the x and y planes for each mouse were summed to represent total ambulation, and ray breaks in the z plane were summed to obtain vertical activity within a one-hour interval.
[0184] Safety Testing hematology Whole blood was collected via cardiac puncture for blood chemistry. Blood was collected into serum separator tubes and centrifuged at 15,000 rpm for 10 minutes. Serum was collected, frozen, and sent to Charles River Laboratories for chemistry testing. Hematology analyses prioritized liver enzymes and glucose chemistry.
[0185] histopathology At necropsy, muscles were fresh frozen in liquid nitrogen-cooled methylbutane and all other organs were harvested, fixed in formalin, and embedded in paraffin. After processing, tissues were stained with H&E, and slides and all tissues were sent to GEMPath, Inc. for formal review by a veterinary pathologist.
[0186] statistical analysis Data are expressed as the mean ± SEM (error bars) and were analyzed using one-way ANOVA with multiple comparisons between groups assessed by Tukey's post hoc test using GraphPad Prism 5 (GraphPad Software, La Jolla, CA) unless otherwise specified.
[0187] Example 2 Efficiency of systemic delivery of scAAVrh74.tMCK.hSGCA Start a small pilot study and 12 vg dose (5 × 10 based on a 20 g mouse) 13 vg / kg, n=4) in sgca - / - We observed the efficacy of gene delivery by intravenous injection into the lateral tail vein of mice. Immunofluorescence analysis was performed on muscles harvested 4 weeks after gene transfer. The amount of hSGCA transgene expression in seven different limb skeletal muscles: TA, GAS, GLUT, QD, PSOAS, and TRI, and DIA. Mice lacking α-SG showed a complete lack of protein when analyzed by immunofluorescence (Figure 2A; representative images of TA, GAS, TRI, and DIA). 1 × 10 12 The therapeutic dose of the total dose of vg resulted in an average of 54 ± 23.81% vector transduction across all skeletal muscles, including the DIA, 4 weeks after gene delivery.
[0188] sgca - / - Dose-escalation study of scAAVrh74.tMCK.hSGCA delivered systemically to mice To determine the safest and most effective dose, delivery of three separate doses of vector was studied in a dose-escalation study in 4-week-old SGCA mice. - / -The lateral tail vein of mice was transfected with 1 x 10 of scAAVrh74.tMCK.hSGCA. 12 vg(5×10 13 vg / kg), total dose 3 × 10 12 Total dose of vg (1 × 10 14 vg / kg), or 6 × 10 12 Total dose of vg (2 × 10 14 Mice were euthanized 12 weeks after gene delivery to assess hSGCA transgene expression in TA, GAS, QD, GLUT, PSOAS, TRI, DIA, and HRT muscles using immunofluorescence. 12 Total dose of vg (5 × 10 13 The mean hSGCA expression in mice treated with 3×10 12 Total dose of vg (1 × 10 14 The mean hSGCA expression in mice treated with the intermediate dose of 6 × 10 vg / kg was 85.35 ± 2.36% in all skeletal muscles. 12 Total dose of vg (2 × 10 14 The average hSGCA expression in mice treated with 100 mg / kg of 1000 mg ...
[0189] Histopathological features of both humans and mice lacking α-SG protein include central nucleation, irregular fiber size distribution, necrosis, and fibrosis. H&E staining was used to visualize muscle morphology, including fiber size and central nucleation (Figure 3). As shown in Figure 3A and 3B, normalization of fiber size distribution similar to that observed in wild-type controls was observed in vehicle-treated sgca mice. - / - sgca treated with scAAVrh74.tMCK.hSGCA compared to control - / - observed in TA, QD, and TRI mice. The mean diameter size of fibers was significantly increased at all doses in TA, QD, and TRI muscles compared to vehicle-treated sgca- / - control mice (Table 1). [Table 1]
[0190] sgca treated with scAAVrh74.tMCK.hSGCA - / - A decrease in central nucleation was also observed in vehicle-treated sgca mice. - / - Skeletal muscle from mice had 68.72 ± 3.01% fibers with centrally located nuclei. After treatment with scAAVrh74.tMCK.hSGCA, the overall value of central nucleation across all muscle tissues was decreased at the lowest dose of scAAVrh74.tMCK.hSGCA, resulting in 55.60 ± 3.25% of skeletal muscle fibers exhibiting centrally located nuclei (Table 2). [Table 2]
[0191] Mice treated with the intermediate dose had 61.85 ± 4.00% of myofibers with central nuclei, whereas nucleation in myofibers treated with the highest dose was reduced to 37.93 ± 12.46% (Figure 3C).
[0192] Fibrosis, in which tissue is overcome by collagen, often occurs in the muscles of LGMD patients, leading to the formation of scar tissue. Fibrosis was assessed using picrosirius red staining to detect collagen I and III content as a marker of fibrosis. As shown in Figure 4, a strong reduction in red staining was observed in sgca− / − mice after treatment with scAAVrh74.tMCK.hSGCA. Quantification revealed that the amount of red staining was significantly reduced in sgca− / − mice treated with scAAVrh74.tMCK.hSGCA compared to vehicle-treated sgca− / − mice. - / - Compared to control mice, collagen content across all muscles was significantly reduced (Figure 4B). Together, these data support the strong expression and function of sgca in muscle tissue. - / - We demonstrate successful systemic delivery of the hSGCA transgene, as shown by the amelioration of histopathological features associated with the lack of α-SG protein in mice.
[0193] Example 3 scAAVrh74.tMCK.hSGCA rAAV improves diaphragm and tibialis anterior muscle function and enhances exercise capacity Because proximal muscle weakness and loss of function are major symptoms of LGMD2D and respiratory failure is the leading cause of death in LGMD2D, improving function and strength of the TA and DIA is essential to increase the length and quality of life of controls with LGMD2D. Using strips of DIA and whole TA muscles, we confirmed the correlation between hSGCA expression and muscle strength. As shown in Figure 5A and 5B, compared to wild-type mice, sgca - / - Deficits in specific force and resistance to contraction-induced damage were noted in the specific force of TA and DIA muscles of untreated mice.
[0194] sgca - / - The TA muscle of mice exhibited a significant impairment of 44% in terms of reduced specific force output (161.6 ± 8.20 mN / mm, respectively) compared to wild-type mice. 2 291.7±6.17mN / mm 2; p < 0.0001), as well as a greater loss of force from forces produced following a strict eccentric contraction protocol (sgca - / - Twelve weeks after tail vein delivery, applicants noticed a dramatic improvement in specific force output following treatment with low, intermediate, and high doses of scAAVrh74.tMCK.hSGCA, which increased to 218±11.94 mN / mm, respectively (Figure 5A). 2 , 227±11.7mN / mm 2 , and 255±11.7mN / mm 2 Resistance to injury following an eccentric contraction protocol was also increased in vehicle-treated SGCAs. - / - Compared to mice treated with the low, medium, and high doses, mice treated with sgca - / - mice lost only 22.0 ± 4.0%, 22.0 ± 3.0%, and 12.0 ± 1.0% (p < 0.0001), respectively (Figure 5A).
[0195] Vehicle-treated sgca - / - In the DIA of mice, the specific force generated showed a 41% decrease in strength (131.5 ± 12.07 mN / mm) compared to wild-type mice. 2 223.8±15.85mN / mm 2 Improved force was observed after treatment with scAAVrh74.tMCK.hSGCA at all three doses, with specific force at the DIA of 179.2 ± 21.03 mN / mm in low-dose mice. 2 to 201.2 ± 22.94 mN / mm in the intermediate dose mice. 2 in the high-dose mice, it increased to 261.46 ± 9.73 mN / mm 2 These data indicate that sgca - / - The TA and DIA muscles of mice had force deficits and showed faster wasting than wild-type mice, however, functional recovery was achieved after delivery of scAAVrh74.tMCK.hSGCA.
[0196] Additional symptoms of LGMD2D include exercise intolerance and reduced activity and ambulation, possibly due to muscle damage, causing pain and muscle fatigue. To assess the level of physical activity, the SGCA - / - and wild-type C57BL / 6 mice were subjected to an open-field activity protocol similar to that used in a previous report. The locomotor-related activity of the mice was monitored to assess the sgca - / - We determined whether the lack of α-SG in mice results in reduced locomotion compared to wild-type mice. The graph in Figure 5C shows the effect of α-SG on the ambulation of sgca mice compared to wild-type controls. - / - Decreased walking and vertical standing in mouse models. - / - The average horizontal ambulatory light break recorded in mice was 2000 ± 159 light breaks / hour, compared to 8911 ± 1193 light breaks / hour in wild-type controls, representing a 77.5% reduction in ambulation. - / - The mean vertical standing light breaks recorded in mice was 24.75 ± 11.47 light breaks / hour, compared to 803.3 ± 55.03 light breaks / hour in wild-type mice, a 97% decrease in vertical standing. Following treatment with scAAVrh74.tMCK.hSGCA, the walking and vertical standing activity of mice increased 12 weeks after gene delivery. The mean horizontal walking increased by 1 × 10 12 3595 ± 55.03 light interruptions / hour, 3 × 10 12 5238 ± 861.9 light interruptions / hour in mice treated with a total dose of 6 × 10 12 The mean vertical standing activity was increased to 6487 ± 467.9 light breaks / hour in mice treated with a total dose of vg. 12 377 ± 146.1 light interruptions / hour, 3 × 10 12 321 ± 126.1 light breaks / hour in mice treated with a total dose of 6 × 10 12 The physical activity of mice treated with the total dose of VG increased to 448.8 ± 53.43 light breaks / hour (Figure 5C). - / -The treated groups showed a 44%–69% improvement in walking and a 92%–94% improvement in vertical standing compared to untreated mice. Furthermore, serum creatine kinase levels were significantly reduced in all treatment groups compared to untreated mice (Figure 5D). Together, these data suggest that delivery of α-SG restores physical activity and inhibits SGCA activation. - / - Protects against muscle destruction in mice.
[0197] Safety and biodistribution analysis of scAAVrh74.tMCK.hSGCA As a safety measure, blood chemistry and hematology studies were performed in SGCA who received the vector. - / - and wild-type mice. All values were within the normal reference range for mice (Figure 6). Furthermore, sgca administered scAAVrh74.tMCK.hSGCA - / - All muscle and organ tissue sections stained with H&E from wild-type and scAAVrh74.tMCK.hSGCA-treated mice were sent to a veterinary pathologist for formal review. - / - No adverse effects were observed in samples from either scAAVrh74.tMCK.hSGCA or wild-type mice. In addition to efficacy, these data demonstrate that systemic delivery of all three doses of scAAVrh74.tMCK.hSGCA was well tolerated, safe, and effective in treating sgca - / - and demonstrated to be non-toxic to wild-type mice.
[0198] To test for potential toxicity or safety concerns due to delivery of scAAVrh74.tMCK.hSGCA, vector biodistribution quantitative PCR was performed to quantify the presence of vector genomes (Figure 7A). A vector-specific tMCK.hSGCA primer probe set was used to quantify the presence of vector genomes in sgca administered scAAVrh74.tMCK / hSGCA. - / - The vector genome was detected in all muscles and organs tested from mice. As expected, the vector genome was present in the tissues tested, with the highest copy number in the liver, followed by muscle. - / -Western blots of alpha-sarcoglycan protein in the livers of WT and sgca − / − mice treated with either LR) or scAArh74.tMCK.hSGCA are shown in Figure 7B .
[0199] To improve the efficiency of α-SG expression, in one embodiment, the hSGCA cDNA sequence is packaged into a self-complementary vector. Self-complementary AAV vectors contain an inverted repeat genome that promotes the formation of dsDNA, allowing replication and transcription without the need for multiple vector genomes to facilitate these processes. Thus, the use of a self-complementary vector eliminates a rate-limiting step that allows for more rapid expression of the transgene. Applicant has demonstrated that intravascular delivery of scAAVrh74.tMCK.hSGCA in LGMD2D patients is achieved with a 1×10 12 and 3 × 10 12 These results show that the α-SG expression is associated with an increase 180 days after gene transfer at a dose of
[0200] Intravenous delivery of scAAVrh74.tMCK.hSGCA provided increased muscle strength and resistance to contraction-induced damage in the tibialis anterior and diaphragm muscles in all three vector-treated cohorts compared to vehicle-treated controls. In addition, treatment with scAAVrh74.tMCK.hSGCA resulted in a significant reduction in CK. Furthermore, after treatment with scAAVrh74.tMCK.hSGCA, mice walked and reared more frequently than vehicle-treated mice.
[0201] Marked histopathology, including centrally located nuclei, wide variation in fiber size, inflammation, necrosis, and fibrosis, is typically observed through muscle biopsies of LGMD2D patients. Following hSGCA delivery, mice had reduced CN, a more uniform distribution of muscle fiber size, and reduced collagen content, and muscles had an overall healthy appearance compared to vehicle-treated mice. The overall reduction in histopathology and scar tissue was concomitantly associated with improved overall normal function and physiology of the muscles of vector-treated mice.
[0202] Finally, safety studies conducted through quantitative PCR, serum chemistry analysis, and histopathology identified no signs of toxicity. The tMCK promoter was only detected in the target tissues (all muscle) and was absent in other (non-muscle) organs except the liver. Detection of tMCK in the liver is neither unusual nor of concern as it is a clearance organ. Histopathological review of all tissues (including liver) by a board-certified veterinary pathologist confirmed not only that systemic delivery of scAAVrh74.tMCK.hSGCA was safe in all tissues, but also that gene delivery was not observed in vehicle-treated sgca. - / - They concluded that it dramatically reduces the amount of dystrophic pathology seen in the skeletal muscle of mice. Chemistry performed on blood samples from vector-treated mice also confirms the lack of toxicity.
[0203] As disclosed herein, the dose escalation study was conducted using the lowest dose tested systemically herein, i.e., a total of 1×10 12 vg(5×10 13 We provide preclinical data supporting that a dose of 100 mg / kg (vg / kg) is sufficient to reduce signs and symptoms associated with loss of α-SG protein. At the lowest dose tested, functional improvements in all muscles, as demonstrated by increases in strength and motor behavior (walking and rearing), were observed in mice treated with the vector. In safety studies, a total of 6 × 10 12 vg(2×10 14 Even at the highest delivered dose of 1000 mg / kg, no signs of toxicity were observed.
[0204] Example 4 Elderly patients and persistent rAAVrh74.tMCK.hSGCA-mediated gene replacement has shown positive results in treating LGMD-2D and other related diseases. This study was designed to test the ability of rAAVrh74.tMCK.hSGCA to treat older, more severely affected muscles and to determine the long-term persistence of the AAV viral vector.
[0205] All procedures were performed in accordance with approval by the Research Institute at the Nationwide Children's Hospital Institutional Animal Care and Use Committee. Mice were maintained under standardized conditions with a 12:12 h light / dark cycle and were provided with food and water ad libitum. Initially, rAAVrh74.tMCK.hSGCA was administered in three doses (1.0 × 10 12 , 3.0×10 12 , and 6.0 × 10 12 12-month-old SGCA with severe muscle histopathology in vg - / - Mice (n=5) were administered the drug systemically via tail vein injection. Controls included sgca mice injected with lactated Ringer's solution (LRS). - / - Mice (n=5) and BL6 wild-type mice (n=4) injected with LRS were included. At an endpoint of 6 months post-treatment, muscles from treated mice were evaluated for SCGA protein expression, histological rescue, and functional improvement. All three doses demonstrated robust protein expression of α-SG in the sarcolemma, improved histopathology, increased locomotor activity and specific force production, protection against eccentric force loss, and reduced serum CK compared to controls. No vector toxicity was detected. In aged mice, treatment resulted in widespread high levels of protein expression in analyzed muscles, reduced fibrosis, and increased resistance to contraction-induced injury in the tibialis anterior muscle.
[0206] In particular, 12-month-old sgca - / - IV administration of rAAVrh74.tMCK.hSGCA in mice resulted in widespread high levels of protein expression throughout the muscles of the lower limbs, upper limbs, and proximal trunk, including the diaphragm and heart (Fig. 8 ).
[0207] After administration of scAAVrh74.tMCK.hSGCA, we observed an overall improvement in muscle pathology (Figure 9A) and a reduction in central nucleation. In addition, mean fiber size increased after administration to levels similar to those of WT fibers in the gastrocnemius (GAS) and triceps brachii (TRI) muscles (Figure 9B).
[0208] The level of collagen deposition was quantified as a measure of fibrosis. Administration of scAAVrh74.tMCK.hSGCA resulted in a reduction in the level of fibrosis compared to untreated controls (Figure 9c). Functional improvement following administration of scAAVrh74.tMCK.hSGCA was evidenced by improved force output (specific force) in the tibialis anterior (TA) and diaphragm (DIA) muscles, and increased resistance to contraction-induced injury in the TA muscle (Figure 10).
[0209] To further investigate the long-term persistence of gene therapy, 4-week-old SGCA - / - Mice are systemically administered rAAVrh74.tMCK.hSGCA. Over 24 months post-treatment, vector genome copy numbers are detected by qPCR across all transduced muscles tested (TA, TRI, DIA, GLUT, PSOAS, GAS, and QUAD). Protein expression and localization are studied by immunofluorescence staining of treated muscles.
[0210] While the present disclosure has been described in terms of specific embodiments, those skilled in the art will recognize that variations and modifications thereof occur, and therefore only such limitations as appear in the claims should be placed on the present disclosure.
[0211] All documents referenced in this application are incorporated herein by reference in their entirety. SEQ ID NO:1 SGCA cDNA codon optimized sequence: SEQ ID NO:2 Human SGCA protein sequence: MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPEHVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGLQVIEVTAYNRDSFDTTRQRLVLEIGDPEGPLLPYQAEFLVRSHDAEEVLPSTPASRFLSALGGLWEPGELQLLNVTSALDRGGRVPLPIEGRKE GVYIKVGSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTLVDKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLVALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAASREVPRPLSTLPMFNVHTGERLPPRVDSAQVPLILDQH* SEQ ID NO:3 tMCK promoter sequence: CCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTGGATCCACTACGGGTCTATGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTGGACCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTCCTCCCTGGGGACAGCCCCTCCTGGCTAGTCACACCCTGTAGGCTCCTCTATATAACCCAGGGGCACAGGGGCTGCCCCCGGGTCAC Sequence number 4 AAVrh74-tMCK-SGCA:
Chem.
Chem.
Chem.
Chem.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Adeno-associated viral vector delivery of β-sarcoglycan and microRNA-29 and treatment of muscular dystrophy
JP2019513399A
Adeno-associated viral vector delivery of alpha-sarcoglycan and treatment of muscular dystrophy
JP7532503B2
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013078316A1
